

CALIFORNIA STATE BOARD OF BEHAVIORAL SCIENCES BILL ANALYSIS

BILL NUMBER: AB 2011 **VERSION:** INTRODUCED FEBRUARY 17, 2026

AUTHOR: HART **SPONSOR:** NUMEROUS (SEE BELOW)

RECOMMENDED POSITION: SUPPORT

SUBJECT: NONQUANTITATIVE TREATMENT LIMITATIONS

Summary: This bill seeks to strengthen California’s mental health parity law by codifying the 2024 Federal Mental Health Parity and Addiction Equity Act rules into California law. This is in response to the Trump Administration stating that it will not enforce the 2024 rules pending litigation surrounding them.

Existing Law:

- 1) Requires every health care service plan or disability insurance policy that provides hospital, medical or surgical coverage to also provide coverage for medically necessary treatment of mental health and substance use disorders under the same terms and conditions applied to other medical conditions. (Health and Safety Code (HSC) §1374.72(a), Insurance Code (IC) §10144.5(a))
- 2) Defines “medically necessary treatment of a mental health or substance use disorder” as a service or product that addresses specific patient needs to prevent, diagnose, or treat an illness, injury, condition or its symptoms. It must be in accordance with the generally accepted standards of care, clinically appropriate, and not primarily for the economic benefit of the insurance plan or the convenience of the patient or health care provider (HSC §1374.72(a)(3), IC §10144.5(a)(3))
- 3) Requires the terms and conditions for benefits that must be applied equally include maximum annual and lifetime benefits, copayments/coinsurance, individual and family deductibles, and out-of-pocket maximums. (HSC §1374.72(c), IC §10144.5(c))
- 4) The Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) is a federal law that requires health plans that offer mental health or substance use disorder benefits to ensure that financial requirements (e.g., copays and deductibles) and treatment limitations (e.g., visit limits) are no more restrictive than those applied to medical/surgical benefits. MHPAEA applies directly to most employer-sponsored group health plans with more than 50 employees.

This Bill:

- 1) Defines a nonquantitative treatment limitation (NQTL) as including, but not limited to, the following (HSC §1374.77(b), IC §10144.43(b)):
 - Medical management standards such as prior authorization, that limit or exclude benefits based on medical necessity or appropriateness or if a treatment is experimental.
 - Prescription drug formulary design.
 - Network tiers with preferred providers and participating providers.
 - Standards related to network composition, such as standards for provider and facility admission to participate in network, methods for determining reimbursement rates and credentialing standards.
 - Methods for determining out-of-network rates such as allowed amounts and usual, customary and reasonable charges.
 - Step therapy protocols.
 - Exclusions based on failure to complete a course of treatment.
 - Criteria that limit the scope or duration of benefits under the plan, such as geographic location restrictions, facility type, or provider specialty.
- 2) Prohibits a health care service plan or insurer from relying on discriminatory factors or evidentiary standards to design an NQTL for mental health or substance use disorder benefits. A factor or standard is discriminatory if the evidence or standards for the factor are biased or non-objective in a manner that discriminates against mental health or substance use disorder benefits compared to medical/surgical benefits in a way that disfavors access. (HSC §1374.77(c), IC §10144.43(c))
- 3) To make sure mental health or substance use disorder NQTLs in a classification are no more restrictive than medical/surgical NQTLs in the classification, the health care service plan or insurer must collect and evaluate relevant data and assess the impact on relevant outcomes for mental health/substance use disorder benefits and medical/surgical benefits, including material access differences, and consider that impact as part of the plan's evaluation. (HSC §1374.77(d), IC §10144.43(d))
- 4) Requires a health care services plan or insurer that provides both medical/surgical benefits and mental health/substance use disorder benefits that imposes NQTLs on mental health/substance use disorder benefits to perform and document comparative analyses of the design and application of each NQTL applicable to

mental health/substance use disorder benefits, containing specified information. (HSC §1374.77(e), IC §10144.43(e))

- 5) Requires the comparative analysis be made available to Department of Managed Health Care and the Department of Insurance annually, and also available upon request to another applicable state authority or a health plan enrollee. (HSC §1374.77(f), IC §10144.43(f))
- 6) Defines penalties and actions to be taken for noncompliance. (HSC §1374.77(g), IC §10144.43(g))

Comments:

- 1) **Author's Intent.** In their fact sheet for the bill, the author's office states the following:

"In 2008, Congress passed the Mental Health Parity and Addiction Equity Act (MHPAEA) to prevent health plans and insurers from imposing more restrictive requirements for mental health and substance use disorder (MH/SUD) treatment than they do for medical and surgical care. Enforcement of the law since, however, has been inconsistent. Regulators have faced ongoing challenges proving non-quantitative treatment limits, such as prior authorization, medical necessity standards, network adequacy, and reimbursement policies, are equal between MH/SUD and physical illnesses. The lack of clarity has made it more difficult for patients to obtain mental health services. In 2024, the Biden administration issued a new federal rule clarifying requirements for plans and insurers to collect data and conduct comparative analyses to measure the impact of non-quantitative treatment limits. Plans and insurers are also required to take reasonable action, if necessary, to create parity between MH/SUD benefits and traditional medical coverage. "

The author notes that the Trump Administration has said it will not enforce the 2024 federal regulations while litigation is pending. Therefore, they are seeking to codify the federal regulations into California law so that they will remain valid in California even if the federal rules are weakened or not implemented.

The author's office did state that there are some areas of the federal rules that were not codified. This is strategic, as there are some instances where existing California law is stronger than federal law. Therefore, provisions that might weaken state law were not included.

The author's office also provided the Board with the document shown in **Attachment A**, which is designed to assist states in understanding and implementing the 2024 federal regulations.

- 2) **Pending Litigation.** The litigation pending on the 2024 federal regulations is The ERISA Industry Committee vs. United States Department of Health and Human

Services et al. The plaintiff, ERISA Industry Committee, is a national advocacy organization that represents large employers that provide health, retirement, and other benefits to the workforce. They are alleging that the federal regulation oversteps the federal agency's authority and violates the Administrative Procedure Act, the Fifth Amendment, and the nondelegation doctrine.

3) Recommended Position. At its meeting on April 17, 2026, the Policy and Advocacy Committee recommended that the Board consider taking a "support" position on this bill.

4) Previous Legislation.

- SB 855 (Chapter 151, Statutes of 2020) expanded upon California's existing mental health parity act to require health plans and insurers to cover all medically necessary treatment of mental health and substance use disorders under the same terms and conditions applied to other medical conditions.
- AB 88 (Chapter 534, Statutes of 1999) required health plans and insurers to provide coverage for the diagnosis and medically necessary treatment of severe mental illness (for persons of any age), and for serious emotional disturbances of a child under the same terms and conditions applied to other medical conditions.

Support and Opposition.

Support

- California Academy of Child and Adolescent Psychiatry (sponsor)
- California State Association of Psychiatrists (sponsor)
- Steinberg Institute (sponsor)
- The Kennedy Forum (sponsor)
- Insurance Commissioner Ricardo Lara / California Department of Insurance (sponsor)
- California Alliance of Child and Family Services
- California Association of Alcohol and Drug Program Executives, Inc.
- California Behavioral Health Association
- California Chronic Care Coalition
- California Coalition for Behavioral Health
- California Psychological Association
- Coalition for Developmental Approaches
- County Behavioral Health Directors Association
- Greenhouse Therapy Center
- Inseparable
- MCG Health
- Mental Health America of California
- National Health Law Program
- National Union of Healthcare Workers

- The California Association of Local Behavioral Health Boards and Commissions

Oppose

- Association of California Life & Health Insurance Companies
- California Association of Health Plans

History

04/09/26 Read second time. Ordered to third reading.
04/08/26 From committee: Do pass. (Ayes 10. Noes 4.) (April 8).
03/25/26 From committee: Do pass and re-refer to Com. on APPR. (Ayes 13. Noes 2.) (March 24). Re-referred to Com. on APPR.
03/02/26 Referred to Com. on HEALTH.
02/18/26 From printer. May be heard in committee March 20.
02/17/26 Read first time. To print.

Attachment

Attachment A: Parity Final Rule: State Codification Gold Standards (Prepared April 2025, The Kennedy Forum and Legal Action Center)

Blank Page

Introduced by Assembly Member Hart
(Principal coauthor: Senator Wiener)

February 17, 2026

An act to add Section 1374.77 to the Health and Safety Code, and to add Section 10144.43 to the Insurance Code, relating to health care coverage.

legislative counsel's digest

AB 2011, as introduced, Hart. Nonquantitative treatment limitations.

Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law also provides for the regulation of health insurers by the Department of Insurance.

Existing federal law, the federal Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA), requires group health plans and health insurance issuers that provide both medical and surgical benefits and mental health or substance use disorder benefits to ensure that financial requirements and treatment limitations applicable to mental health or substance use disorder benefits are no more restrictive than the predominant requirements or limitations applied to substantially all medical and surgical benefits. Existing state law requires every health care service plan and disability insurance policy issued, amended, or renewed on or after January 1, 2021, that provides hospital, medical, or surgical coverage to provide coverage for medically necessary treatment of mental health and substance use

disorders under the same terms and conditions applied to other medical conditions, as specified.

This bill would prohibit a health care service plan or insurer from relying upon discriminatory factors or evidentiary standards to design a nonquantitative treatment limitation (NQTL) to be imposed on mental health or substance use disorder benefits, as specified. To ensure that an NQTL applicable to mental health or substance use disorder benefits in a classification is no more restrictive than the predominant NQTL applied to substantially all medical/surgical benefits in the classification, the bill would require a health care service plan or insurer to collect and evaluate relevant data to assess the impact of the NQTL on outcomes related to access to mental health and substance use disorder benefits and medical/surgical benefits. The bill would require specified health care service plans or insurers to perform and document comparative analyses of the design and application of each NQTL applicable to mental health or substance use disorder benefits in accordance with prescribed requirements and submit the analyses to the respective departments by January 1, 2027, and annually thereafter. If the departments make a final determination of noncompliance, the bill would require the health care service plan or insurer to, among other things, notify all enrollees or insureds of its noncompliance with the requirements of parity. If a health care service plan or insurer receives a final determination of noncompliance with these provisions with respect to an NQTL or with the requirements of the MHPAEA, the bill would deem the NQTL to be a violation of parity and authorize the respective department to direct the plan or insurer not to impose the NQTL, as provided. The bill would define terms for purposes of these provisions and make related findings and declarations. Because a violation of these requirements by a health care service plan would be a crime, the bill would impose a state-mandated local program.

The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.

This bill would provide that no reimbursement is required by this act for a specified reason.

Vote: majority. Appropriation: no. Fiscal committee: yes.
State-mandated local program: yes.

The people of the State of California do enact as follows:

1 SECTION 1. (a) The Legislature finds and declares all of the
2 following:

3 (1) Mental health conditions and substance use disorders affect
4 millions of individuals and families across the United States and
5 are among the leading causes of disability, lost productivity,
6 preventable illness, and premature death.

7 (2) Timely access to effective mental health and substance use
8 disorder treatment is essential to individual well-being, family
9 stability, workforce participation, public safety, and the overall
10 health of communities.

11 (3) Historically, health insurance coverage for mental health
12 and substance use disorder benefits has been subject to
13 discriminatory limitations, higher cost sharing, more restrictive
14 utilization management practices, and narrower provider networks
15 than coverage for medical and surgical benefits.

16 (4) The federal Paul Wellstone and Pete Domenici Mental
17 Health Parity and Addiction Equity Act of 2008 (MHPAEA) was
18 enacted to address these inequities by requiring that financial
19 requirements and treatment limitations applicable to mental health
20 and substance use disorder benefits be no more restrictive than
21 those applied to medical and surgical benefits.

22 (5) Despite the enactment of the MHPAEA, federal and state
23 enforcement actions, parity compliance reviews, and consumer
24 complaints have consistently demonstrated persistent and systemic
25 noncompliance, particularly with respect to nonquantitative
26 treatment limitations, including prior authorization, medical
27 necessity standards, network composition, and reimbursement
28 practices.

29 (6) Inconsistent interpretation and application of parity
30 requirements have contributed to ongoing barriers to care, including
31 delays in treatment, denials of medically necessary services,
32 provider shortages, and increased out-of-pocket costs for patients
33 and families.

34 (7) Following implementation of earlier federal parity
35 regulations, federal agencies identified the need for additional
36 clarification, specificity, and operational guidance to ensure that
37 existing statutory parity requirements were applied consistently

1 and effectively, particularly with respect to nonquantitative
2 treatment limitations.

3 (8) In 2024, federal agencies issued final rules interpreting and
4 implementing the MHPAEA that clarified existing statutory
5 obligations, articulated standards for evaluating parity compliance,
6 and specified documentation, transparency, and analytical
7 requirements necessary for effective enforcement.

8 (9) The 2024 federal final rules, as published in the Federal
9 Register Volume 89, Number 184 on September 23, 2024,
10 emphasize that parity compliance must be demonstrated both as
11 written and in operation, including through meaningful analysis
12 of the impact of nonquantitative treatment limitations on access
13 to mental health and substance use disorder benefits.

14 (10) Strong parity protections are particularly critical for children
15 and youth, older adults, individuals with disabilities, veterans,
16 communities of color, rural residents, and others who face
17 disproportionate barriers to accessing mental health and substance
18 use disorder services.

19 (11) Effective enforcement of mental health parity laws reduces
20 preventable crises, including avoidable psychiatric hospitalizations,
21 emergency department utilization, homelessness, incarceration,
22 and overdose deaths, while supporting early intervention and
23 recovery-oriented care.

24 (12) Recent litigation challenging federal parity regulations has
25 created uncertainty regarding the continued availability and
26 enforceability of the protections articulated in the 2024 federal
27 final rules, notwithstanding the underlying statutory requirements
28 of the MHPAEA.

29 (13) Under existing state law, including Section 10144.4 of the
30 Insurance Code and Section 1374.76 of the Health and Safety
31 Code, the Department of Insurance and the Department of Managed
32 Health Care are responsible for enforcing mental health parity
33 requirements and have authority to implement and administer
34 parity laws consistent with their existing regulatory powers.

35 (b) Based on the findings, the Legislature declares all of the
36 following:

37 (1) Full and faithful implementation of the MHPAEA is a matter
38 of significant public interest and is essential to achieving equity
39 in health care coverage and outcomes.

1 (2) The 2024 federal final rules reflect authoritative
2 interpretations of existing parity obligations and provide necessary
3 clarity regarding how those obligations are to be evaluated,
4 documented, and enforced.

5 (3) It is the intent of the Legislature that the provisions enacted
6 by this act be construed as codifying and preserving existing parity
7 protections, not as establishing new health care benefit mandates
8 or expanding the scope of required covered services.

9 (4) It is further the intent of the Legislature to ensure continuity,
10 stability, and enforceability of parity protections under state law
11 in the event of any repeal, amendment, or invalidation of federal
12 parity regulations.

13 (5) This act affirms and clarifies the authority of the Department
14 of Insurance and the Department of Managed Health Care,
15 consistent with their existing statutory powers, to issue regulations,
16 guidance, and enforcement actions necessary to implement and
17 enforce mental health parity requirements.

18 (6) By codifying these standards in state law, the Legislature
19 seeks to promote transparency, accountability, and effective
20 oversight of parity compliance, while avoiding unnecessary
21 duplication, disruption, or additional administrative burden.

22 SEC. 2. Section 1374.77 is added to the Health and Safety
23 Code, immediately following Section 1374.76, to read:

24 1374.77. (a) For purposes of this section, the following
25 definitions apply:

26 (1) (A) “Medical/surgical benefits” means benefits with respect
27 to items or services for medical conditions or surgical procedures,
28 as defined under the terms of the health care service plan contract
29 and in accordance with applicable federal and state law, but does
30 not include mental health benefits or substance use disorder
31 benefits.

32 (B) Notwithstanding subparagraph (A), any condition or
33 procedure defined by the health care service plan contract as being
34 or as not being a medical condition or surgical procedure shall be
35 defined consistently with generally recognized independent
36 standards of current medical practice. To the extent that generally
37 recognized independent standards of current medical practice do
38 not address whether a condition or procedure is a medical condition
39 or surgical procedure, a health care service plan contract may

1 define the condition or procedure in accordance with applicable
2 federal and state law.

3 (2) (A) “Mental health benefits” means benefits with respect
4 to items or services for mental health conditions, as defined under
5 the terms of the health care service plan contract and in accordance
6 with applicable federal and state law, but does not include
7 medical/surgical benefits or substance use disorder benefits.

8 (B) Notwithstanding subparagraph (A), any condition defined
9 by the health care service plan contract as being or as not being a
10 mental health condition shall be defined consistently with generally
11 recognized independent standards of current medical practice. For
12 purposes of this paragraph, to be consistent with generally
13 recognized independent standards of current medical practice, the
14 definition shall include all conditions covered under the health
15 care service plan contract, except for substance use disorders, that
16 fall under any of the diagnostic categories listed in the mental,
17 behavioral, and neurodevelopmental disorders chapter of the most
18 recent version of the International Classification of Diseases (ICD)
19 or that are listed in the most recent version of the Diagnostic and
20 Statistical Manual of Mental Disorders (DSM).

21 (C) To the extent that generally recognized independent
22 standards of current medical practice do not address whether a
23 condition is a mental health condition, a health care service plan
24 contract may define the condition in accordance with applicable
25 federal and state law.

26 (3) (A) “Substance use disorder benefits” means benefits with
27 respect to items or services for substance use disorders, as defined
28 under the terms of the health care service plan contract and in
29 accordance with applicable federal and state law, but does not
30 include medical/surgical benefits or mental health benefits.

31 (B) Notwithstanding subparagraph (A), any disorder defined
32 by the health care service plan as being or as not being a substance
33 use disorder shall be defined consistently with generally recognized
34 independent standards of current medical practice. For purposes
35 of this paragraph, to be consistent with generally recognized
36 independent standards of current medical practice, the definition
37 shall include all disorders covered under the health care service
38 plan contract that fall under any of the diagnostic categories listed
39 as a mental or behavioral disorder due to psychoactive substance
40 use, or equivalent category, in the mental, behavioral, and

1 neurodevelopmental disorders chapter, or equivalent chapter, of
2 the most recent version of the ICD or that are listed as a
3 substance-related and addictive disorder, or equivalent category,
4 in the most recent version of the DSM.

5 (C) To the extent that generally recognized independent
6 standards of current medical practice do not address whether a
7 disorder is a substance use disorder, a health care service plan
8 contract may define the disorder in accordance with applicable
9 federal and state law.

10 (b) For purposes of this section, a nonquantitative treatment
11 limitation (NQTL) includes, but is not limited to, all of the
12 following:

13 (1) Medical management standards, including, for example,
14 prior authorization, that limit or exclude benefits based on medical
15 necessity or medical appropriateness, or based on whether the
16 treatment is experimental or investigative.

17 (2) Formulary design for prescription drugs.

18 (3) For health care service plans with multiple network tiers,
19 including, for example, preferred providers and participating
20 providers, network tier design.

21 (4) Standards related to network composition, including, but
22 not limited to, standards for provider and facility admission to
23 participate in a network or for continued network participation,
24 including methods for determining reimbursement rates,
25 credentialing standards, and procedures for ensuring the network
26 includes an adequate number of each category of provider and
27 facility to provide services under the plan contract.

28 (5) Health care service plan methods for determining
29 out-of-network rates, including, for example, allowed amounts;
30 usual, customary, and reasonable charges; or application of other
31 external benchmarks for out-of-network rates.

32 (6) Refusal to pay for higher cost therapies until it can be shown
33 that a lower cost therapy is not effective, also known as fail-first
34 policies or step therapy protocols.

35 (7) Exclusions based on failure to complete a course of
36 treatment.

37 (8) Restrictions based on geographic location, facility type,
38 provider specialty, and other criteria that limit the scope or duration
39 of benefits for services provided under the plan contract.

1 (c) (1) For purposes of determining comparability and
 2 stringency under this section, a health care service plan shall not
 3 rely upon discriminatory factors or evidentiary standards to design
 4 an NQTL to be imposed on mental health or substance use disorder
 5 benefits. A factor or evidentiary standard is discriminatory if the
 6 information, evidence, sources, or standards for the factor or
 7 evidentiary standard are biased or not objective in a manner that
 8 discriminates against mental health or substance use disorder
 9 benefits as compared to medical/surgical benefits.

10 (2) (A) For purposes of this subdivision, information, evidence,
 11 sources, or standards are considered to be biased or not objective
 12 in a manner that discriminates against mental health or substance
 13 use disorder benefits as compared to medical/surgical benefits if,
 14 based on all of the relevant facts and circumstances, the
 15 information, evidence, sources, or standards systematically disfavor
 16 access or are specifically designed to disfavor access to mental
 17 health or substance use disorder benefits as compared to
 18 medical/surgical benefits.

19 (B) For purposes of this paragraph, relevant facts and
 20 circumstances include, but are not limited to, all of the following:

21 (i) The reliability of the source of the information, evidence,
 22 sources, or standards, including any underlying data.

23 (ii) The independence of the information, evidence, sources,
 24 and standards relied upon.

25 (iii) The analyses and methodologies employed to select the
 26 information and the consistency of their application.

27 (iv) Any known safeguards deployed to prevent reliance on
 28 skewed data or metrics.

29 (C) Information, evidence, sources, or standards are not
 30 considered biased or not objective if the health care service plan
 31 has taken the steps necessary to correct, cure, or supplement any
 32 information, evidence, sources, or standards that would have been
 33 biased or not objective in the absence of those steps.

34 (3) For purposes of this subdivision, historical plan data or other
 35 historical information from a time when the health care service
 36 plan was not subject to, or not in compliance with, Section 2726
 37 of the federal Public Health Service Act (42 U.S.C. Sec. 300gg-26)
 38 is considered to be biased or not objective in a manner that
 39 discriminates against mental health or substance use disorder
 40 benefits as compared to medical/surgical benefits if the historical

1 plan data or other historical information systematically disfavors
2 access or is specifically designed to disfavor access to mental
3 health or substance use disorder benefits as compared to
4 medical/surgical benefits, and the health care service plan has not
5 taken the steps necessary to correct, cure, or supplement the data
6 or information.

7 (d) (1) To ensure that an NQTL applicable to mental health or
8 substance use disorder benefits in a classification, in operation, is
9 no more restrictive than the predominant NQTL applied to
10 substantially all medical/surgical benefits in the classification, a
11 health care service plan shall collect and evaluate relevant data in
12 a manner reasonably designed to assess the impact of the NQTL
13 on relevant outcomes related to access to mental health and
14 substance use disorder benefits and medical/surgical benefits and
15 carefully consider the impact as part of the plan's evaluation.

16 (2) As part of its evaluation, the health care service plan shall
17 not disregard relevant outcomes data that it knows, or reasonably
18 should know, suggests that an NQTL is associated with material
19 differences in access to mental health or substance use disorder
20 benefits as compared to medical/surgical benefits. The department
21 may specify in guidance the type, form, and manner of collection
22 and evaluation for the data required under this subdivision.

23 (e) (1) A health care service plan that provides both
24 medical/surgical benefits and mental health or substance use
25 disorder benefits and that imposes any nonquantitative treatment
26 limitations (NQTLs) on mental health or substance use disorder
27 benefits shall perform and document comparative analyses of the
28 design and application of each NQTL applicable to mental health
29 or substance use disorder benefits. Each comparative analysis shall
30 comply with the requirements of this section.

31 (2) With respect to each NQTL applicable to a mental health
32 or substance use disorder benefit under a health care service plan
33 contract, the comparative analysis shall include, at minimum, the
34 information provided under this section. In addition to the
35 comparative analysis for each NQTL limitation, a health care
36 service plan shall also prepare and make available to the
37 department, upon request, a written list of all NQTLs imposed
38 under the plan contract.

1 (3) Each comparative analysis shall include, with respect to the
 2 NQTL that is the subject of the comparative analysis, all of the
 3 following:

4 (A) Identification of the NQTL, including the specific terms of
 5 the plan contract or other relevant terms regarding the NQTL, the
 6 policies or guidelines in which the NQTL appears or is described,
 7 and the applicable sections of any other relevant documents,
 8 including provider contracts, that describe the NQTL.

9 (B) Identification of all mental health or substance use disorder
 10 benefits and medical/surgical benefits to which the NQTL applies,
 11 including a list of which benefits are considered mental health or
 12 substance benefits, and which benefits are considered
 13 medical/surgical benefits.

14 (C) A description of which benefits are included in each
 15 classification.

16 (4) Each comparative analysis shall include, with respect to
 17 every factor considered or relied upon to design the NQTL or apply
 18 the NQTL to mental health or substance use disorder benefits and
 19 medical/surgical benefits, all of the following:

20 (A) Identification of every factor considered or relied upon, as
 21 well as the evidentiary standards considered or relied upon to
 22 design or apply each factor and the sources from which each
 23 evidentiary standard was derived, in determining which mental
 24 health or substance use disorder benefits and which
 25 medical/surgical benefits are subject to the NQTL.

26 (B) A definition of each factor that includes all of the following:

27 (i) A detailed description of the factor.

28 (ii) A description of each evidentiary standard used to design
 29 or apply each factor, and the source of each evidentiary standard,
 30 identified under subparagraph (A).

31 (iii) A description of any steps the plan has taken to correct,
 32 cure, or supplement any information, evidence, sources, or
 33 standards that would otherwise have been considered biased or
 34 not objective in the absence of those steps.

35 (5) Each comparative analysis shall include a description of
 36 how each factor identified under paragraph (4) is used in the design
 37 or application of the NQTL to mental health and substance use
 38 disorder benefits and medical/surgical benefits in a classification.

39 The description shall include all of the following:

1 (A) A detailed explanation of how each factor identified under
2 paragraph (4) is used to determine which mental health or substance
3 use disorder benefits and which medical/surgical benefits are
4 subject to the NQTL.

5 (B) An explanation of the evidentiary standards or other
6 information or sources, if any, considered or relied upon in
7 designing or applying the factors or relied upon in designing and
8 applying the NQTL, including in the determination of whether and
9 how mental health or substance use disorder benefits or
10 medical/surgical benefits are subject to the NQTL.

11 (C) If the application of the factor depends on specific decisions
12 made in the administration of benefits, the description shall include
13 the nature of the decisions, the timing of the decisions, and the
14 professional designations and qualifications of each decisionmaker.

15 (D) If more than one factor is identified and defined under
16 paragraph (4), an explanation of all of the following:

17 (i) How all of the factors relate to each other.

18 (ii) The order in which all of the factors are applied, including
19 when they are applied.

20 (iii) Whether and how any factors are given more weight than
21 others.

22 (iv) The reasons for the ordering and weighting of the factors.

23 (v) Any deviations or variations from a factor, its applicability,
24 or its definition, including the evidentiary standards used to define
25 the factor and the information or sources from which each
26 evidentiary standard was derived. This includes, but is not limited
27 to, how the factor is used differently to apply the NQTL to mental
28 health or substance use disorder benefits as compared to
29 medical/surgical benefits, and a description of how the plan
30 establishes those deviations or variations.

31 (6) Each comparative analysis shall evaluate whether, in any
32 classification, under the terms of the plan contract as written, any
33 processes, strategies, evidentiary standards, or other factors used
34 in designing and applying the NQTL to mental health or substance
35 use disorder benefits are comparable to, and applied no more
36 stringently than, the processes, strategies, evidentiary standards,
37 or other factors used in designing and applying the NQTL with
38 respect to medical/surgical benefits. Each comparative analysis
39 shall include, with respect to the NQTL and the factors used in
40 designing and applying the NQTL, all of the following:

- 1 (A) Documentation of each factor identified and defined under
 2 paragraph (4) that was applied to determine whether the NQTL
 3 applies to mental health or substance use disorder benefits and
 4 medical/surgical benefits in a classification, including, as relevant,
 5 both the following:
- 6 (i) Quantitative data, calculations, or other analyses showing
 7 whether, in each classification in which the NQTL applies, mental
 8 health or substance use disorder benefits and medical/surgical
 9 benefits met or did not meet any applicable threshold identified in
 10 the relevant evidentiary standard to determine that the NQTL would
 11 or would not apply.
 - 12 (ii) Records maintained by the plan documenting the
 13 consideration and application of all factors and evidentiary
 14 standards, as well as the results of their application.
- 15 (B) In each classification in which the NQTL applies to mental
 16 health or substance use disorder benefits, a comparison of how the
 17 NQTL, as written, is designed and applied to mental health or
 18 substance use disorder benefits and to medical/surgical benefits,
 19 including the specific provisions of any forms, checklists,
 20 procedure manuals, or other documentation used in designing and
 21 applying the NQTL or that address the application of the NQTL.
- 22 (C) Documentation demonstrating how the factors are
 23 comparably applied, as written, to mental health or substance use
 24 disorder benefits and medical/surgical benefits in each
 25 classification, to determine which benefits are subject to the NQTL.
- 26 (D) An explanation of the reasons for any deviations or
 27 variations in the application of a factor used to apply the NQTL,
 28 or the application of the NQTL, to mental health or substance use
 29 disorder benefits as compared to medical/surgical benefits, and
 30 how the plan establishes those deviations or variations, including
 31 any of the following:
- 32 (i) In the definition of the factors, the evidentiary standards used
 33 to define the factors, and the sources from which the evidentiary
 34 standards were derived.
 - 35 (ii) In the design of the factors or evidentiary standards.
 - 36 (iii) In the application or design of the NQTL.
- 37 (7) Each comparative analysis shall evaluate whether, in any
 38 classification, in operation, the processes, strategies, evidentiary
 39 standards, or other factors used in designing and applying the
 40 NQTL to mental health or substance use disorder benefits are

1 comparable to, and are applied no more stringently than, the
2 processes, strategies, evidentiary standards, or other factors used
3 in designing and applying the NQTL with respect to
4 medical/surgical benefits. Each comparative analysis shall include,
5 with respect to the NQTL and the factors used in designing and
6 applying the NQTL, all of the following:

7 (A) An explanation of any methodology and underlying data
8 used to demonstrate the application of the NQTL in operation.

9 (B) The sample period, inputs used in any calculations,
10 definitions of terms used, and any criteria used to select the mental
11 health or substance use disorder benefits and medical/surgical
12 benefits to which the NQTL is applicable.

13 (C) With respect to an NQTL for which relevant data is
14 temporarily unavailable, a detailed explanation of the lack of
15 relevant data, the basis for the plan's conclusion that there is a lack
16 of relevant data, and when and how the data will become available
17 and be collected and analyzed.

18 (D) With respect to an NQTL for which no data exists that can
19 reasonably assess any relevant impact of the NQTL on relevant
20 outcomes related to access to mental health and substance use
21 disorder benefits and medical/surgical benefits, a reasoned
22 justification as to the basis for the conclusion that there is no data
23 that can reasonably assess the NQTL's impact, an explanation of
24 why the nature of the NQTL prevents the plan from reasonably
25 measuring its impact, an explanation of what data was considered
26 and rejected, and documentation of any additional safeguards or
27 protocols used to ensure that the NQTL complies with applicable
28 parity laws.

29 (E) Identification of the relevant data collected and evaluated.

30 (F) Documentation of the outcomes that resulted from the
31 application of the NQTL to mental health or substance use disorder
32 benefits and medical/surgical benefits, including both of the
33 following:

34 (i) The evaluation of relevant data.

35 (ii) A reasoned justification and analysis that explains why the
36 plan concluded that any differences in the relevant data do or do
37 not suggest the NQTL contributes to material differences in access
38 to mental health or substance use disorder benefits as compared
39 to medical/surgical benefits.

1 (G) A detailed explanation of any material differences in access
2 demonstrated by the outcomes evaluated under subparagraph (F),
3 including both of the following:

4 (i) A reasoned explanation of any material differences in access
5 that are not attributable to differences in the comparability or
6 relative stringency of the NQTL as applied to mental health or
7 substance use disorder benefits and medical/surgical benefits,
8 including any considerations beyond a plan's control that contribute
9 to the existence of material differences and a detailed explanation
10 of the bases for concluding that material differences are not
11 attributable to differences in the comparability or relative
12 stringency of the NQTL.

13 (ii) To the extent differences in access to mental health or
14 substance use disorder benefits are attributable to generally
15 recognized independent professional medical or clinical standards
16 or carefully circumscribed measures reasonably and appropriately
17 designed to detect or prevent and prove fraud and abuse that
18 minimize the negative impact on access to appropriate mental
19 health and substance use disorder benefits, and those standards or
20 measures are used as the basis for a factor or evidentiary standard
21 used to design or apply an NQTL, documentation explaining how
22 any differences are attributable to those standards or measures.

23 (H) A discussion of the actions that have been or are being taken
24 by the plan to address any material differences in access to mental
25 health or substance use disorder benefits as compared to
26 medical/surgical benefits, including the actions the plan has taken
27 or is taking to address material differences to comply with parity
28 laws, including, as applicable, both of the following:

29 (i) A reasoned explanation of any material differences in access
30 to mental health or substance use disorder benefits as compared
31 to medical/surgical benefits that persist despite reasonable actions
32 that have been or are being taken.

33 (ii) For a plan designing and applying one or more NQTLs
34 related to network composition, a discussion of the actions that
35 have been or are being taken to address material differences in
36 access to in-network mental health and substance use disorder
37 benefits as compared to in-network medical/surgical benefits.

38 (8) The comparative analysis shall address the findings and
39 conclusion as to the comparability of the processes, strategies,
40 evidentiary standards, and other factors used in designing and

1 applying the NQTL to mental health or substance use disorder
2 benefits and medical/surgical benefits within each classification,
3 and the relative stringency of their application, both as written and
4 in operation, and include all of the following:

5 (A) Any findings or conclusions indicating that the plan is or
6 is not, or might or might not be, in compliance with the
7 requirements of applicable parity laws, including any additional
8 actions the plan has taken or intends to take to address any potential
9 areas of concern or noncompliance.

10 (B) A reasoned and detailed discussion of the findings and
11 conclusions described in subparagraph (A).

12 (C) Citations to any additional information not otherwise
13 included in the comparative analysis that supports the findings and
14 conclusions described in subparagraph (A).

15 (D) The date the analysis is completed and the title and
16 credentials of all relevant persons who participated in the
17 performance and documentation of the comparative analysis.

18 (E) If the comparative analysis relies upon an evaluation by a
19 reviewer or consultant considered by the plan to be an expert, an
20 assessment of each expert’s qualifications and the extent to which
21 the plan ultimately relied upon each expert’s evaluation in
22 performing and documenting the comparative analysis of the design
23 and application of the NQTL applicable to both mental health or
24 substance use disorder benefits and medical/surgical benefits.

25 (f) (1) In addition to making a comparative analysis available
26 to the department on an annual basis, a health care service plan
27 shall make available a copy of the comparative analysis when
28 requested by either of the following:

29 (A) Any applicable state authority.

30 (B) An enrollee or an enrollee’s authorized representative.

31 (2) A health care service plan shall provide the comparative
32 analysis no later than 30 calendar days after receiving a request
33 under this subdivision.

34 (3) A health care service plan shall not withhold any information
35 contained in the comparative analysis, including any information
36 from or developed by third parties.

37 (g) (1) A health care service plan shall submit the comparative
38 analyses to the department by January 1, 2027, and annually
39 thereafter, in the manner required by this section.

1 (2) If the department makes a final determination of
2 noncompliance, the health care service plan shall notify all
3 enrollees that the plan has been determined to not be in compliance
4 with the requirements of parity or this section with respect to the
5 plan contract. The notice shall be provided within seven business
6 days of receipt of the final determination of noncompliance, and
7 the health care service plan shall provide a copy of the notice to
8 the department, any service provider involved in the claims process,
9 and any fiduciary responsible for deciding benefit claims within
10 the same timeframe.

11 (3) The notice to enrollees shall be written in a manner
12 calculated to be understood by the average enrollee and shall
13 include, in plain language, the following information in a
14 standalone notice:

15 (A) The following statement prominently displayed on the first
16 page, in no less than 14-point font: “Attention! The California
17 Department of Managed Health Care has determined that (insert
18 the name of the health care service plan) is not in compliance with
19 the federal Paul Wellstone and Pete Domenici Mental Health Parity
20 and Addiction Equity Act of 2008.”

21 (B) A summary of changes the health care service plan has made
22 as part of its corrective action plan specified to the director
23 following the initial determination of noncompliance, including
24 an explanation of any opportunity for an enrollee to have a claim
25 for benefits submitted or reprocessed.

26 (C) A summary of the department’s final determination that the
27 health care service plan is not in compliance with parity or this
28 section, including any provisions or practices identified as being
29 in violation, additional corrective actions identified by the
30 department in the final determination notice, and information on
31 how enrollees may obtain from the health care service plan a copy
32 of the final determination of noncompliance.

33 (D) Any additional actions the health care service plan is taking
34 to come into compliance with parity or this section, when the health
35 care service plan will take those actions, and a clear and accurate
36 statement explaining whether the director has concurred with those
37 actions.

38 (E) Contact information for questions and complaints, and a
39 statement explaining how enrollees may obtain more information
40 about the notice, including both of the following:

1 (i) The health care service plan’s telephone number and an email
2 or internet website.

3 (ii) The department’s telephone number and email or internet
4 website.

5 (F) The health care service plan shall make the notice available
6 in paper form or electronically, including by email or a posting on
7 its internet website, according to the following requirements:

8 (i) The format is readily accessible.

9 (ii) The notice provided in paper form is free of charge and is
10 provided upon request.

11 (iii) If the electronic form is a posting on the health care service
12 plan’s internet website, the health care service plan timely notifies
13 the enrollee in paper form or email that the documents are available
14 on the internet, provides a link to the internet website, includes
15 the statement required in this section, and notifies the enrollee that
16 the documents are available in paper form upon request.

17 (G) If a health care service plan receives a final determination
18 from the department that the health care service plan is not in
19 compliance with the comparative analysis requirements with
20 respect to an NQTL, or that the health care service plan is not in
21 compliance with the requirements of the federal Paul Wellstone
22 and Pete Domenici Mental Health Parity and Addiction Equity
23 Act of 2008 (29 U.S.C. Sec. 1185a), the NQTL shall be deemed
24 a violation of parity and, in addition to the existing penalty
25 authority provided under Section 1390, the department may direct
26 the health care service plan not to impose the NQTL with respect
27 to mental health or substance use disorder benefits in the relevant
28 classification, unless and until the health care service plan
29 demonstrates to the department compliance with the requirements
30 of this section or with federal law or takes appropriate action to
31 remedy the violation.

32 SEC. 3. Section 10144.43 is added to the Insurance Code,
33 immediately following Section 10144.4, to read:

34 10144.43. (a) For purposes of this section, the following
35 definitions apply:

36 (1) (A) “Medical/surgical benefits” means benefits with respect
37 to items or services for medical conditions or surgical procedures,
38 as defined under the terms of the health insurance policy and in
39 accordance with applicable federal and state law, but does not
40 include mental health benefits or substance use disorder benefits.

1 (B) Notwithstanding subparagraph (A), any condition or
2 procedure defined by the health insurance policy as being or as
3 not being a medical condition or surgical procedure shall be defined
4 consistently with generally recognized independent standards of
5 current medical practice. To the extent that generally recognized
6 independent standards of current medical practice do not address
7 whether a condition or procedure is a medical condition or surgical
8 procedure, a health insurance policy may define the condition or
9 procedure in accordance with applicable federal and state law.

10 (2) (A) “Mental health benefits” means benefits with respect
11 to items or services for mental health conditions, as defined under
12 the terms of the health insurance policy and in accordance with
13 applicable federal and state law, but does not include
14 medical/surgical benefits or substance use disorder benefits.

15 (B) Notwithstanding subparagraph (A), any condition defined
16 by the health insurance policy as being or as not being a mental
17 health condition shall be defined consistently with generally
18 recognized independent standards of current medical practice. For
19 purposes of this paragraph, to be consistent with generally
20 recognized independent standards of current medical practice, the
21 definition shall include all conditions covered under the health
22 insurance policy, except for substance use disorders, that fall under
23 any of the diagnostic categories listed in the mental, behavioral,
24 and neurodevelopmental disorders chapter of the most recent
25 version of the International Classification of Diseases (ICD) or
26 that are listed in the most recent version of the Diagnostic and
27 Statistical Manual of Mental Disorders (DSM).

28 (C) To the extent that generally recognized independent
29 standards of current medical practice do not address whether a
30 condition is a mental health condition, a health insurance policy
31 may define the condition in accordance with applicable federal
32 and state law.

33 (3) (A) “Substance use disorder benefits” means benefits with
34 respect to items or services for substance use disorders, as defined
35 under the terms of the health insurance policy and in accordance
36 with applicable federal and state law, but does not include
37 medical/surgical benefits or mental health benefits.

38 (B) Notwithstanding subparagraph (A), any disorder defined
39 by the health insurance policy as being or as not being a substance
40 use disorder shall be defined consistently with generally recognized

1 independent standards of current medical practice. For purposes
2 of this paragraph, to be consistent with generally recognized
3 independent standards of current medical practice, the definition
4 shall include all disorders covered under the health insurance policy
5 that fall under any of the diagnostic categories listed as a mental
6 or behavioral disorder due to psychoactive substance use, or
7 equivalent category, in the mental, behavioral, and
8 neurodevelopmental disorders chapter, or equivalent chapter, of
9 the most recent version of the ICD or that are listed as a
10 substance-related and addictive disorder, or equivalent category,
11 in the most recent version of the DSM.

12 (C) To the extent that generally recognized independent
13 standards of current medical practice do not address whether a
14 disorder is a substance use disorder, a health insurance policy may
15 define the disorder in accordance with applicable federal and state
16 law.

17 (b) For purposes of this section, a nonquantitative treatment
18 limitation (NQTL) includes, but is not limited to, all of the
19 following:

20 (1) Medical management standards, including, for example,
21 prior authorization, that limit or exclude benefits based on medical
22 necessity or medical appropriateness, or based on whether the
23 treatment is experimental or investigative.

24 (2) Formulary design for prescription drugs.

25 (3) For insurers with multiple network tiers, including, for
26 example, preferred providers and participating providers, network
27 tier design.

28 (4) Standards related to network composition, including, but
29 not limited to, standards for provider and facility admission to
30 participate in a network or for continued network participation,
31 including methods for determining reimbursement rates,
32 credentialing standards, and procedures for ensuring the network
33 includes an adequate number of each category of provider and
34 facility to provide services under the policy.

35 (5) Insurer methods for determining out-of-network rates,
36 including, for example, allowed amounts; usual, customary, and
37 reasonable charges; or application of other external benchmarks
38 for out-of-network rates.

- 1 (6) Refusal to pay for higher cost therapies until it can be shown
 2 that a lower cost therapy is not effective, also known as fail-first
 3 policies or step therapy protocols.
- 4 (7) Exclusions based on failure to complete a course of
 5 treatment.
- 6 (8) Restrictions based on geographic location, facility type,
 7 provider specialty, and other criteria that limit the scope or duration
 8 of benefits for services provided under the policy.
- 9 (c) (1) For purposes of determining comparability and
 10 stringency under this section, an insurer shall not rely upon
 11 discriminatory factors or evidentiary standards to design an NQTL
 12 to be imposed on mental health or substance use disorder benefits.
 13 A factor or evidentiary standard is discriminatory if the
 14 information, evidence, sources, or standards for the factor or
 15 evidentiary standard are biased or not objective in a manner that
 16 discriminates against mental health or substance use disorder
 17 benefits as compared to medical/surgical benefits.
- 18 (2) (A) For purposes of this subdivision, information, evidence,
 19 sources, or standards are considered to be biased or not objective
 20 in a manner that discriminates against mental health or substance
 21 use disorder benefits as compared to medical/surgical benefits if,
 22 based on all of the relevant facts and circumstances, the
 23 information, evidence, sources, or standards systematically disfavor
 24 access or are specifically designed to disfavor access to mental
 25 health or substance use disorder benefits as compared to
 26 medical/surgical benefits.
- 27 (B) For purposes of this paragraph, relevant facts and
 28 circumstances include, but are not limited to, all of the following:
- 29 (i) The reliability of the source of the information, evidence,
 30 sources, or standards, including any underlying data.
- 31 (ii) The independence of the information, evidence, sources,
 32 and standards relied upon.
- 33 (iii) The analyses and methodologies employed to select the
 34 information and the consistency of their application.
- 35 (iv) Any known safeguards deployed to prevent reliance on
 36 skewed data or metrics.
- 37 (C) Information, evidence, sources, or standards are not
 38 considered biased or not objective if the insurer has taken the steps
 39 necessary to correct, cure, or supplement any information,

1 evidence, sources, or standards that would have been biased or not
2 objective in the absence of those steps.

3 (3) For purposes of this subdivision, historical policy data or
4 other historical information from a time when the insurer was not
5 subject to, or not in compliance with, Section 2726 of the federal
6 Public Health Service Act (42 U.S.C. Sec. 300gg-26) is considered
7 to be biased or not objective in a manner that discriminates against
8 mental health or substance use disorder benefits as compared to
9 medical/surgical benefits if the historical policy data or other
10 historical information systematically disfavors access or is
11 specifically designed to disfavor access to mental health or
12 substance use disorder benefits as compared to medical/surgical
13 benefits, and the insurer has not taken the steps necessary to correct,
14 cure, or supplement the data or information.

15 (d) (1) To ensure that an NQTL applicable to mental health or
16 substance use disorder benefits in a classification, in operation, is
17 no more restrictive than the predominant NQTL applied to
18 substantially all medical/surgical benefits in the classification, an
19 insurer shall collect and evaluate relevant data in a manner
20 reasonably designed to assess the impact of the NQTL on relevant
21 outcomes related to access to mental health and substance use
22 disorder benefits and medical/surgical benefits and carefully
23 consider the impact as part of the insurer's evaluation.

24 (2) As part of its evaluation, the insurer shall not disregard
25 relevant outcomes data that it knows, or reasonably should know,
26 suggests that an NQTL is associated with material differences in
27 access to mental health or substance use disorder benefits as
28 compared to medical/surgical benefits. The department may specify
29 in guidance the type, form, and manner of collection and evaluation
30 for the data required under this section.

31 (e) (1) An insurer that provides both medical/surgical benefits
32 and mental health or substance use disorder benefits and that
33 imposes any NQTLs on mental health or substance use disorder
34 benefits shall perform and document comparative analyses of the
35 design and application of each NQTL applicable to mental health
36 or substance use disorder benefits. Each comparative analysis shall
37 comply with the requirements of this section.

38 (2) With respect to each NQTL applicable to a mental health
39 or substance use disorder benefit under an insurance policy, the
40 comparative analysis shall include, at minimum, the information

1 provided under this section. In addition to the comparative analysis
2 for each NQTL limitation, an insurer shall also prepare and make
3 available to the department, upon request, a written list of all
4 NQTLs imposed under the policy.

5 (3) Each comparative analysis shall include, with respect to the
6 NQTL that is the subject of the comparative analysis, all of the
7 following:

8 (A) Identification of the NQTL, including the specific terms of
9 the policy or other relevant terms regarding the NQTL, the policies
10 or guidelines in which the NQTL appears or is described, and the
11 applicable sections of any other relevant documents, including
12 provider contracts, that describe the NQTL.

13 (B) Identification of all mental health or substance use disorder
14 benefits and medical/surgical benefits to which the NQTL applies,
15 including a list of which benefits are considered mental health or
16 substance benefits, and which benefits are considered
17 medical/surgical benefits.

18 (C) A description of which benefits are included in each
19 classification.

20 (4) Each comparative analysis shall include, with respect to
21 every factor considered or relied upon to design the NQTL or apply
22 the NQTL to mental health or substance use disorder benefits and
23 medical/surgical benefits, all of the following:

24 (A) Identification of every factor considered or relied upon, as
25 well as the evidentiary standards considered or relied upon to
26 design or apply each factor and the sources from which each
27 evidentiary standard was derived, in determining which mental
28 health or substance use disorder benefits and which
29 medical/surgical benefits are subject to the NQTL.

30 (B) A definition of each factor that includes all of the following:

31 (i) A detailed description of the factor.

32 (ii) A description of each evidentiary standard used to design
33 or apply each factor, and the source of each evidentiary standard,
34 identified under subparagraph (A).

35 (iii) A description of any steps the insurer has taken to correct,
36 cure, or supplement any information, evidence, sources, or
37 standards that would otherwise have been considered biased or
38 not objective in the absence of those steps.

39 (5) Each comparative analysis shall include a description of
40 how each factor identified under paragraph (4) is used in the design

1 or application of the NQTL to mental health and substance use
2 disorder benefits and medical/surgical benefits in a classification.

3 The description shall include all of the following:

4 (A) A detailed explanation of how each factor identified under
5 paragraph (4) is used to determine which mental health or substance
6 use disorder benefits and which medical/surgical benefits are
7 subject to the NQTL.

8 (B) An explanation of the evidentiary standards or other
9 information or sources, if any, considered or relied upon in
10 designing or applying the factors or relied upon in designing and
11 applying the NQTL, including in the determination of whether and
12 how mental health or substance use disorder benefits or
13 medical/surgical benefits are subject to the NQTL.

14 (C) If the application of the factor depends on specific decisions
15 made in the administration of benefits, the description shall include
16 the nature of the decisions, the timing of the decisions, and the
17 professional designations and qualifications of each decisionmaker.

18 (D) If more than one factor is identified and defined under
19 paragraph (4), an explanation of all of the following:

20 (i) How all of the factors relate to each other.

21 (ii) The order in which all of the factors are applied, including
22 when they are applied.

23 (iii) Whether and how any factors are given more weight than
24 others.

25 (iv) The reasons for the ordering and weighting of the factors.

26 (E) Any deviations or variations from a factor, its applicability,
27 or its definition, including the evidentiary standards used to define
28 the factor and the information or sources from which each
29 evidentiary standard was derived. This includes, but is not limited
30 to, how the factor is used differently to apply the NQTL to mental
31 health or substance use disorder benefits as compared to
32 medical/surgical benefits, and a description of how the insurer
33 establishes those deviations or variations.

34 (6) Each comparative analysis shall evaluate whether, in any
35 classification, under the terms of the policy as written, any
36 processes, strategies, evidentiary standards, or other factors used
37 in designing and applying the NQTL to mental health or substance
38 use disorder benefits are comparable to, and applied no more
39 stringently than, the processes, strategies, evidentiary standards,
40 or other factors used in designing and applying the NQTL with

1 respect to medical/surgical benefits. Each comparative analysis
2 shall include, with respect to the NQTL and the factors used in
3 designing and applying the NQTL, all of the following:

4 (A) Documentation of each factor identified and defined under
5 paragraph (4) that was applied to determine whether the NQTL
6 applies to mental health or substance use disorder benefits and
7 medical/surgical benefits in a classification, including, as relevant,
8 both the following:

9 (i) Quantitative data, calculations, or other analyses showing
10 whether, in each classification in which the NQTL applies, mental
11 health or substance use disorder benefits and medical/surgical
12 benefits met or did not meet any applicable threshold identified in
13 the relevant evidentiary standard to determine that the NQTL would
14 or would not apply.

15 (ii) Records maintained by the insurer documenting the
16 consideration and application of all factors and evidentiary
17 standards, as well as the results of their application.

18 (B) In each classification in which the NQTL applies to mental
19 health or substance use disorder benefits, a comparison of how the
20 NQTL, as written, is designed and applied to mental health or
21 substance use disorder benefits and to medical/surgical benefits,
22 including the specific provisions of any forms, checklists,
23 procedure manuals, or other documentation used in designing and
24 applying the NQTL or that address the application of the NQTL.

25 (C) Documentation demonstrating how the factors are
26 comparably applied, as written, to mental health or substance use
27 disorder benefits and medical/surgical benefits in each
28 classification, to determine which benefits are subject to the NQTL.

29 (D) An explanation of the reasons for any deviations or
30 variations in the application of a factor used to apply the NQTL,
31 or the application of the NQTL, to mental health or substance use
32 disorder benefits as compared to medical/surgical benefits, and
33 how the insurer establishes those deviations or variations, including
34 any of the following:

35 (i) In the definition of the factors, the evidentiary standards used
36 to define the factors, and the sources from which the evidentiary
37 standards were derived.

38 (ii) In the design of the factors or evidentiary standards.

39 (iii) In the application or design of the NQTL.

1 (7) Each comparative analysis shall evaluate whether, in any
2 classification, in operation, the processes, strategies, evidentiary
3 standards, or other factors used in designing and applying the
4 NQTL to mental health or substance use disorder benefits are
5 comparable to, and are applied no more stringently than, the
6 processes, strategies, evidentiary standards, or other factors used
7 in designing and applying the NQTL with respect to
8 medical/surgical benefits. Each comparative analysis shall include,
9 with respect to the NQTL and the factors used in designing and
10 applying the NQTL, all of the following:

11 (A) An explanation of any methodology and underlying data
12 used to demonstrate the application of the NQTL in operation.

13 (B) The sample period, inputs used in any calculations,
14 definitions of terms used, and any criteria used to select the mental
15 health or substance use disorder benefits and medical/surgical
16 benefits to which the NQTL is applicable.

17 (C) With respect to an NQTL for which relevant data is
18 temporarily unavailable, a detailed explanation of the lack of
19 relevant data, the basis for the insurer's conclusion that there is a
20 lack of relevant data, and when and how the data will become
21 available and be collected and analyzed.

22 (D) With respect to an NQTL for which no data exists that can
23 reasonably assess any relevant impact of the NQTL on relevant
24 outcomes related to access to mental health and substance use
25 disorder benefits and medical/surgical benefits, a reasoned
26 justification as to the basis for the conclusion that there is no data
27 that can reasonably assess the NQTL's impact, an explanation of
28 why the nature of the NQTL prevents the insurer from reasonably
29 measuring its impact, an explanation of what data was considered
30 and rejected, and documentation of any additional safeguards or
31 protocols used to ensure that the NQTL complies with applicable
32 parity laws.

33 (E) Identification of the relevant data collected and evaluated.

34 (F) Documentation of the outcomes that resulted from the
35 application of the NQTL to mental health or substance use disorder
36 benefits and medical/surgical benefits, including both of the
37 following:

38 (i) The evaluation of relevant data.

39 (ii) A reasoned justification and analysis that explains why the
40 insurer concluded that any differences in the relevant data do or

1 do not suggest the NQTL contributes to material differences in
2 access to mental health or substance use disorder benefits as
3 compared to medical/surgical benefits.

4 (G) A detailed explanation of any material differences in access
5 demonstrated by the outcomes evaluated under subparagraph (F),
6 including both of the following:

7 (i) A reasoned explanation of any material differences in access
8 that are not attributable to differences in the comparability or
9 relative stringency of the NQTL as applied to mental health or
10 substance use disorder benefits and medical/surgical benefits,
11 including any considerations beyond an insurer's control that
12 contribute to the existence of material differences and a detailed
13 explanation of the bases for concluding that material differences
14 are not attributable to differences in the comparability or relative
15 stringency of the NQTL.

16 (ii) To the extent differences in access to mental health or
17 substance use disorder benefits are attributable to generally
18 recognized independent professional medical or clinical standards
19 or carefully circumscribed measures reasonably and appropriately
20 designed to detect or prevent and prove fraud and abuse that
21 minimize the negative impact on access to appropriate mental
22 health and substance use disorder benefits, and those standards or
23 measures are used as the basis for a factor or evidentiary standard
24 used to design or apply an NQTL, documentation explaining how
25 any differences are attributable to those standards or measures.

26 (H) A discussion of the actions that have been or are being taken
27 by the insurer to address any material differences in access to
28 mental health or substance use disorder benefits as compared to
29 medical/surgical benefits, including the actions the insurer has
30 taken or is taking to address material differences to comply with
31 parity laws, including, as applicable, both of the following:

32 (i) A reasoned explanation of any material differences in access
33 to mental health or substance use disorder benefits as compared
34 to medical/surgical benefits that persist despite reasonable actions
35 that have been or are being taken.

36 (ii) For an insurer designing and applying one or more NQTLs
37 related to network composition, a discussion of the actions that
38 have been or are being taken to address material differences in
39 access to in-network mental health and substance use disorder
40 benefits as compared to in-network medical/surgical benefits.

1 (8) The comparative analysis shall address the findings and
2 conclusion as to the comparability of the processes, strategies,
3 evidentiary standards, and other factors used in designing and
4 applying the NQTL to mental health or substance use disorder
5 benefits and medical/surgical benefits within each classification,
6 and the relative stringency of their application, both as written and
7 in operation, and include all of the following:

8 (A) Any findings or conclusions indicating that the insurer is
9 or is not, or might or might not be, in compliance with the
10 requirements of applicable parity laws, including any additional
11 actions the insurer has taken or intends to take to address any
12 potential areas of concern or noncompliance.

13 (B) A reasoned and detailed discussion of the findings and
14 conclusions described in subparagraph (A).

15 (C) Citations to any additional information not otherwise
16 included in the comparative analysis that supports the findings and
17 conclusions described in subparagraph (A).

18 (D) The date the analysis is completed and the title and
19 credentials of all relevant persons who participated in the
20 performance and documentation of the comparative analysis.

21 (E) If the comparative analysis relies upon an evaluation by a
22 reviewer or consultant considered by the insurer to be an expert,
23 an assessment of each expert's qualifications and the extent to
24 which the insurer ultimately relied upon each expert's evaluation
25 in performing and documenting the comparative analysis of the
26 design and application of the NQTL applicable to both mental
27 health or substance use disorder benefits and medical/surgical
28 benefits.

29 (f) (1) In addition to making a comparative analysis available
30 to the department on an annual basis, an insurer shall make
31 available a copy of the comparative analysis when requested by
32 either of the following:

33 (A) Any applicable state authority.

34 (B) An insured or an insured's authorized representative.

35 (2) An insurer shall provide the comparative analysis no later
36 than 30 calendar days after receiving a request under this
37 subdivision.

38 (3) An insurer shall not withhold any information contained in
39 the comparative analysis, including any information from or
40 developed by third parties.

1 (g) (1) An insurer shall submit the comparative analyses to the
2 department by January 1, 2027, and annually thereafter, in the
3 manner required by this section.

4 (2) If the department makes a final determination of
5 noncompliance, the insurer shall notify all insureds that the insurer
6 has been determined to not be in compliance with the requirements
7 of parity or this section with respect to the policy. The notice shall
8 be provided within seven business days of receipt of the final
9 determination of noncompliance, and the insurer shall provide a
10 copy of the notice to the department, any service provider involved
11 in the claims process, and any fiduciary responsible for deciding
12 benefit claims within the same timeframe.

13 (3) The notice to insureds shall be written in a manner calculated
14 to be understood by the average insured and shall include, in plain
15 language, the following information in a standalone notice:

16 (A) The following statement prominently displayed on the first
17 page, in no less than 14-point font: “Attention! The California
18 Department of Insurance has determined that (insert the name of
19 the insurer) is not in compliance with the federal Paul Wellstone
20 and Pete Demonici Mental Health Parity and Addiction Equity
21 Act of 2008.”

22 (B) A summary of changes the insurer has made as part of its
23 corrective action plan specified to the commissioner following the
24 initial determination of noncompliance, including an explanation
25 of any opportunity for an insured to have a claim for benefits
26 submitted or reprocessed.

27 (C) A summary of the department’s final determination that the
28 insurer is not in compliance with parity or this section, including
29 any provisions or practices identified as being in violation,
30 additional corrective actions identified by the department in the
31 final determination notice, and information on how insureds may
32 obtain from the insurer a copy of the final determination of
33 noncompliance.

34 (D) Any additional actions the insurer is taking to come into
35 compliance with parity or this section, when the insurer will take
36 those actions, and a clear and accurate statement explaining
37 whether the commissioner has concurred with those actions.

38 (E) Contact information for questions and complaints, and a
39 statement explaining how insureds may obtain more information
40 about the notice, including both of the following:

1 (i) The insurer's telephone number and an email or internet
2 website.

3 (ii) The department's telephone number and email or internet
4 website.

5 (F) The insurer shall make the notice available in paper form
6 or electronically, including by email or a posting on its internet
7 website, according to the following requirements:

8 (i) The format is readily accessible.

9 (ii) The notice provided in paper form is free of charge and is
10 provided upon request.

11 (iii) If the electronic form is a posting on the insurer's internet
12 website, the insurer timely notifies the insured in paper form or
13 email that the documents are available on the internet, provides a
14 link to the internet website, includes the statement required in this
15 section, and notifies the insured that the documents are available
16 in paper form upon request.

17 (G) If an insurer receives a final determination from the
18 department that the insurer is not in compliance with the
19 comparative analysis requirements with respect to an NQTL, or
20 that the insurer is not in compliance with the requirements of the
21 federal Paul Wellstone and Pete Domenici Mental Health Parity
22 and Addiction Equity Act of 2008 (29 U.S.C. Sec. 1185a), the
23 NQTL shall be deemed a violation of parity and, in addition to the
24 existing penalty authority provided under Sections 10144.5 and
25 10144.52, the department may direct the insurer not to impose the
26 NQTL with respect to mental health or substance use disorder
27 benefits in the relevant classification, unless and until the insurer
28 demonstrates to the department compliance with the requirements
29 of this section or with federal law or takes appropriate action to
30 remedy the violation.

31 SEC. 4. No reimbursement is required by this act pursuant to
32 Section 6 of Article XIII B of the California Constitution because
33 the only costs that may be incurred by a local agency or school
34 district will be incurred because this act creates a new crime or
35 infraction, eliminates a crime or infraction, or changes the penalty
36 for a crime or infraction, within the meaning of Section 17556 of
37 the Government Code, or changes the definition of a crime within

- 1 the meaning of Section 6 of Article XIII B of the California
- 2 Constitution.

O

Parity Final Rule: State Codification Gold Standards

Prepared April 2025

Contents

The State Parity Gold Standards.....	1
Defining and Classifying MH/SUD Benefits	3
Definitions	3
Meaningful Benefits	4
Non-Quantitative Treatment Limitations	5
NQTL Compliance Test Part One: Design & Application: Prohibition on Discriminatory Factors and Evidentiary Standards	6
NQTL Compliance Test Part Two: Outcomes Data & Material Difference Standard	7
Transparency	8
NQTL Comparative Analysis	8
Consumer Access to Information	9
Enforcement	10
Appendix.....	12
Regulatory Language to Codify	12
Defining and Classifying MH/SUD Benefits	12
Non-Quantitative Treatment Limitations	16
Enforcement	26
Penalties	29
References.....	31

The State Parity Gold Standards

Mental health parity enforcement is complex. Each module of the State Parity Gold Standard Toolkit breaks down essential concepts for regulators, advocates, and lawmakers, mapping out a clear map for understanding and implementation.

Ultimately, this enhances fidelity to the federal Parity law, ensuring better access to mental health and substance use treatment for more Americans.

Each toolkit was developed in collaboration with experts to ensure each module provides the most comprehensive set of guidelines for states. For more information about the State Parity Gold Standard Toolkit, contact info@thekennedyforum.org

Learn More

The Kennedy Forum's website:

<https://www.thekennedyforum.org/>

Legal Action Center's website:

<https://www.lac.org/>

In September 2024, the Departments of Labor, Health and Human Services, and Treasury (Tri-agencies) released updated regulations implementing provisions of the Consolidated Appropriations Act of 2021 and updating 2013 regulations implementing the Mental Health Parity and Addiction Equity Act of 2008 (Parity Act). At its foundation, the federal Parity Act bars most health insurance plans from discriminating against mental health and substance use disorder (MH/SUD) benefits when compared to medical and surgical (med/surg) benefits.

The federal Parity Act regulations are the floor, not the ceiling, and “states have significant latitude to impose requirements on health insurance issuers that are more restrictive than the Federal law.”¹

States should explicitly codify – and strengthen – these critical provisions by introducing a bill that includes all of the components of the 2024 regulations.

States can directly incorporate the federal rule as published in September 2024 into statute, or include all its components by including the text in the appendices of this toolkit. This will ensure individuals in state-regulated plans have fair access to mental health and substance use disorder (MH/SUD) care.² In the following pages, we offer more detail on the included components, all of which work together to strengthen parity.

The final rule²⁷:



Focuses attention on access with a data-driven approach



Closes potential loopholes and offers more guidance



Enhances transparency and streamlines oversight

Defining and Classifying MH/SUD Benefits

Definitions ³

The final rule aligns definitions with clinical science, removing any non-clinical considerations from definitions of MH/SUDs. States should align their definitions with the final rule to avoid contradicting, discriminatorily limiting language.

In defining the terms “medical/surgical benefits,” “mental health benefits,” and “substance use disorder benefits,” the final rule makes clear that how a plan characterizes its benefits must be consistent with generally recognized standards of current medical practice – not state guidelines if those conflict. Specifically, coverage for all diagnoses that are listed as MH conditions in the most current version of the International Classification of Diseases (ICD) or the Diagnostic and Statistical Manual of Mental Disorders (DSM) must be considered “mental health benefits,” and coverage for all diagnoses that are listed as SUDs in the most current version of the ICD or DSM must be considered “substance use disorder benefits.”⁴ These updates are particularly important for ensuring parity for people seeking treatment for autism spectrum disorders, eating disorders, and other frequently denied MH conditions, as a number of states have inconsistent definitions that enabled plans to discriminatorily limit coverage for these conditions.



States should update their definitions of these terms in law or regulations to mirror those in the federal regulations – specifically, the alignment with the ICD and DSM – to ensure there is no confusion or misclassification of benefits.

Meaningful Benefits ⁵

The final rule ensures meaningful MH/SUD coverage at all levels by establishing a meaningful benefits standard across all classifications where medical/surgical benefits are offered.

This ensures patients have access to core treatments based on recognized medical standards, not just minimal or ancillary services. Consistent state implementation of this standard is critical to achieve the rule’s intended effect of eliminating discriminatory coverage gaps and ensuring comprehensive MH/SUD care at every level of benefit.

At a minimum, if a plan covers MH/SUD benefits in one classification (inpatient in-network, inpatient out-of-network, outpatient in-network, outpatient out-of-network, emergency care, prescription drugs), it must cover benefits for that condition in all of those classifications. Under the new regulations, such coverage must be “meaningful,” defined as a core treatment for that condition, rather than just screenings or ancillary benefits, to the extent that one or more meaningful medical/surgical benefits are provided in that classification.⁶ Plans are instructed to consult the generally recognized independent standards of current medical practice to determine what benefits are considered meaningful.⁷



States should codify this meaningful benefits standard in law or regulations. As a gold standard, states should add a definition of “meaningful benefits” specifying that plans must follow the generally accepted standards of care which are reflected by published peer-review research and consensus recommendations from non-profit professional societies for the relevant clinical specialty, including LOCUS/CALOCUS for MH benefits and The ASAM Criteria for SUD benefits.

Non-Quantitative Treatment Limitations

The final rule significantly strengthens Parity Act implementation through comprehensive NQTL reforms. It **clarifies critical terminology, eliminates potential compliance loopholes, and requires that NQTLs be comparable in both design and application between MH/SUD and medical/surgical benefits.** The rule **prohibits the use discriminatory factors or standards** that systematically disadvantage MH/SUD care, while **mandating data-driven monitoring** through required analysis plans. Plans must evaluate both individual NQTLs and their aggregate impact on access to care, with particular attention to network adequacy issues. When material differences in access are identified, plans must take reasonable corrective actions to ensure compliance with parity requirements.

Illustrative, Non-Exhaustive List of Non-Quantitative Treatment Limitations ⁸

The Parity Act regulations include a list of non-quantitative treatment limitations (NQTLs), which were updated in the new regulations. The Departments clarified that this list is “non-exhaustive” and that plans must be analyzing all of the NQTLs identified, as well as any others they may employ. The list now identifies prior authorizations, standards related to network composition (including determining reimbursement rates, credentialing standards, and procedures for ensuring an adequate network), and methods for determining out-of-network rates.⁹



If states have a list of NQTLs in law or regulations, this list should be updated to mirror those in the federal regulations. As a gold standard, state agencies should collaborate with consumers and providers to identify any other NQTLs that should be added to this list that pose barriers to accessing MH/SUD benefits.

NQTL Compliance Test | Part One: Design & Application: Prohibition on Discriminatory Factors and Evidentiary Standards ¹⁰

Plans have to show that the way they design and apply NQTLs is comparable and no more stringent for MH and SUD benefits compared to medical and surgical benefits.

In designing NQTLs, plans may no longer use discriminatory factors or evidentiary standards – those that are biased or not objective in a way that systematically disfavors access or are designed to disfavor access to MH and SUD benefits as compared to medical and surgical benefits – unless the plan takes steps to correct, cure, or supplement them. Plans also cannot rely on historical data or information from before the Parity Act was enacted or from a time when the plan was not complying with the Parity Act.¹¹



States should codify this prohibition on discriminatory factors and evidentiary standards in the design of NQTLs in law or regulations.

NQTL Compliance Test | Part Two:

Outcomes Data & Material Difference Standard ¹²


As a new step in demonstrating compliance with the Parity Act, plans must now collect and evaluate relevant outcomes data to assess the impact of all NQTLs on access to benefits. While the rules do not specify the types of data plans must use, they give some examples (such as claims data, in- and out-of-network use, and reimbursement rates), and do not allow plans to disregard data they know or should reasonably know suggest a material difference in access. A material difference in access to MH or SUD benefits compared to medical and surgical benefits is a strong indicator of noncompliance, and plans must take reasonable actions to correct such disparities when they are caused by the NQTL.¹³ State law or private accreditation standards may require specific data.¹⁴



States should codify the requirement that plans collect and evaluate relevant data to assess the impact of the NQTL on outcomes related to access to mental health and substance use disorder benefits. As a gold standard, states should require in law or regulations the specific data points that would be most meaningful or effective. States should also mandate that plans collect and evaluate the relevant data that the Departments have recommended related to network composition:



In-network and out-of-network utilization rates (including data related to provider claim submissions);



Network adequacy metrics (including time and distance data, and data on providers accepting new patients);



Provider reimbursement rates (for comparable services and as benchmarked to a reference standard).²⁸

Transparency

The final rule enhances transparency of compliance. Upon request, plans and issuers are required to provide their comparative analysis to state regulators and consumers or their authorized representatives.

NQTL Comparative Analysis¹⁵

The Consolidated Appropriations Act of 2021 requires plans to perform and document analyses showing that they are designing and applying NQTLs in a comparable way. The updated regulations go into far greater detail about this six-step process and the contents for the comparative analysis.¹⁶

Comparative analyses must include, at minimum:

1. A description of the NQTL and which benefits are subject to the NQTL;
2. Identification and definition of the factors and evidentiary standards used to design or apply the NQTL;
3. A description of how factors are used in the design or application of the NQTL;
4. A demonstration that the NQTL for MH and SUD benefits is comparable to and no more stringent than for medical and surgical benefits as written (i.e. in documents);
5. A demonstration that the NQTL for MH and SUD benefits is comparable to and no more stringent than for medical and surgical benefits in operation, including the outcomes data and their evaluation, an explanation of any material differences in access, and a description of reasonable actions taken to address such differences; and
6. Findings and conclusions.



States should codify this full comparative analysis process and content requirements.

Consumer Access to Information ¹⁷

Consumers or their authorized representatives in any commercial health insurance plan may request their plan's NQTL comparative analysis – which all insurers subject to the Parity Act are required to perform and document – when they receive an adverse benefit determination of MH/SUD benefits, such as a denial or partial denial.¹⁸ Consumers in ERISA plans or their authorized representatives may request these analyses at any time, not just when they receive an adverse benefit determination.¹⁹ Plans may not withhold information from consumers in these analyses by claiming they are proprietary or commercially protected.



States should require all state-regulated insurance plans to provide plan participants or their authorized representatives with the federally-mandated NQTL comparative analysis at any time, not just when they receive an adverse benefit determination, consistent with the requirement for ERISA plans. States should also explicitly codify the requirement that plans may not withhold any information from consumers in these analysis.

For more information on key takeaways of state codification of these standards on consumers, please see the following Legal Action Center resource, for which this brief draws:

<https://www.lac.org/assets/files/LAC-fact-sheet-2024-Parity-Regulations-final.pdf>

Enforcement ²⁰

The final rule establishes mechanisms for enforcement by clarifying the authority of the Departments and states to require remedies for non-compliance, including stopping NQTLs from being imposed.

State regulators may request NQTL comparative analyses at any time²¹ and many states require plans to submit their analyses on a regular basis. Federal regulators must request no fewer than 20 comparative analyses annually. Upon a request from federal regulators, plans must submit these comparative analyses or any additional information within 10 business days. Upon an initial finding of non-compliance, plans must identify actions they will take to comply and provide updated analyses within 45 days. Upon a final determination of non-compliance, plans must notify enrollees within 7 business days and include information about opportunities to have affected claims reprocessed or newly submitted.²² Regulators may require a plan to stop using an NQTL if it does not comply with the Parity Act, or if the plan's analysis was incomplete or insufficient to show it complied with the law.²³ Regulators may also take any other enforcement actions available to them.



States should require plans to submit their NQTL comparative analyses annually, or at a minimum specify how many comparative analyses they will review each year. States should retain the authority to issue a finding of noncompliance for insufficient comparative analyses without a correction period.²⁴ States should also codify the timeframes in which plans must respond to requests and notify plan participants upon a final determination of noncompliance, which should be no less stringent than those in the final rules for federal regulators. States should further provide that a final determination of noncompliance, including when an analysis was incomplete or insufficient, will result in the plan being required to cease using that NQTL. States should also identify and include in law or regulations sufficient penalties to impose on plans for such noncompliance, which can be tied to other legal provisions such as failure to comply with form filings or acts of discrimination and unfair trade practices. States may also wish to consider additional provisions to ensure plans are held accountable for actions or omissions of third-party administrators.

Appendix

Directly Referencing Federal Regulations

“The provisions of 89 Fed. Reg. 77586 et seq., as published on September 23, 2024, and any guidance issued by federal departments of health and human services, labor, and the treasury to implement the rules adopted in September 2024 are incorporated in this section in their entirety.”

If this language is used, there is no need to directly codify any further language.

Regulatory Language to Codify

The following language from the federal regulations can be used directly to codify the federal requirements into state laws. We are happy to work with you to fit these into your laws and regulations as appropriate.

Defining and Classifying MH/SUD Benefits

Appendix I. Definitions (45 C.F.R. 146.136(a)(2))

“Medical/surgical benefits” means benefits with respect to items or services for medical conditions or surgical procedures, as defined under the terms of the group health plan (or health insurance coverage offered by an issuer in connection with such a plan) and in accordance with applicable Federal and State law, but does not include mental health benefits or substance use disorder benefits. Notwithstanding the preceding sentence, any condition or procedure defined by the plan or coverage as being or as not being a medical condition or surgical procedure must be defined consistent with generally recognized independent standards of current medical practice (for example, the most

current version of the ICD). To the extent generally recognized independent standards of current medical practice do not address whether a condition or procedure is a medical condition or surgical procedure, plans and issuers may define the condition or procedure in accordance with applicable Federal and State law.

“Mental health benefits” means benefits with respect to items or services for mental health conditions, as defined under the terms of the group health plan (or health insurance coverage offered by an issuer in connection with such a plan) and in accordance with applicable Federal and State law, but does not include medical/surgical benefits or substance use disorder benefits. Notwithstanding the preceding sentence, any condition defined by the plan or coverage as being or as not being a mental health condition must be defined consistent with generally recognized independent standards of current medical practice. For the purpose of this definition, to be consistent with generally recognized independent standards of current medical practice, the definition must include all conditions covered under the plan or coverage, except for substance use disorders, that fall under any of the diagnostic categories listed in the mental, behavioral, and neurodevelopmental disorders chapter (or equivalent chapter) of the most current version of the ICD or that are listed in the most current version of the DSM. To the extent generally recognized independent standards of current medical practice do not address whether a condition is a mental health condition, plans and issuers may define the condition in accordance with applicable Federal and State law.

“Substance use disorder benefits” means benefits with respect to items or services for substance use disorders, as defined under the terms of the group health plan (or health insurance coverage offered by an issuer in connection with such a plan) and in accordance with applicable Federal and State law, but does not include medical/surgical benefits or mental health benefits. Notwithstanding the preceding sentence, any disorder defined by the plan or coverage as being or as not being a substance use disorder must be defined consistent with generally recognized independent standards of current medical practice. For the purpose of this definition, to be consistent with generally recognized independent standards of current medical practice, the definition must include all disorders covered under the plan or coverage that fall under any of the diagnostic categories listed as a mental or behavioral disorder due to psychoactive substance use (or equivalent category) in the mental, behavioral, and neurodevelopmental disorders chapter (or equivalent chapter) of the most current version of the ICD or that are listed as a Substance-Related and Addictive Disorder (or equivalent category) in the most current version of the DSM. To the extent generally recognized independent standards of current medical practice do not address whether

a disorder is a substance use disorder, plans and issuers may define the disorder in accordance with applicable Federal and State law.

*Appendix II. **Meaningful Benefits (45 C.F.R. § 146.136(c)(2)(ii)(A))***

If a plan (or health insurance coverage) provides any benefits for a mental health condition or substance use disorder in any classification of benefits, it must provide meaningful benefits for that mental health condition or substance use disorder in every classification in which medical/surgical benefits are provided. For purposes of this paragraph, whether the benefits provided are meaningful benefits is determined in comparison to the benefits provided for medical conditions and surgical procedures in the classification and requires, at a minimum, coverage of benefits for that condition or disorder in each classification in which the plan (or coverage) provides benefits for one or more medical conditions or surgical procedures. A plan (or coverage) does not provide meaningful benefits under this paragraph unless it provides benefits for a core treatment for that condition or disorder in each classification in which the plan (or coverage) provides benefits for a core treatment for one or more medical conditions or surgical procedures. For purposes of this paragraph, a core treatment for a condition or disorder is a standard treatment or course of treatment, therapy, service, or intervention indicated by generally recognized independent standards of current medical practice. If there is no core treatment for a covered mental health condition or substance use disorder with respect to a classification, the plan (or coverage) is not required to provide benefits for a core treatment for such condition or disorder in that classification (but must provide benefits for such condition or disorder in every classification in which medical/surgical benefits are provided). In determining the classification in which a particular benefit belongs, a plan (or health insurance issuer) must apply the same standards to medical/surgical benefits and to mental health or substance use disorder benefits.

GOLD STANDARD: Incorporating “generally accepted standards of care”:

If your state has a law requiring “generally accepted standards of care,” we recommend using this language instead of “generally recognized independent standards of current medical practice” and referencing that statutory definition.

- If your state does not have require “generally accepted standards of care,” we recommend adding a definition of “generally recognized independent standards of current medical practice” that mirrors this gold standard [link to toolkit, or insert language here]. For example, see [Colorado HB 25-1102 \(2025\)](#):

If a health benefit plan provides any benefits for a mental health condition or substance use disorder in any classification of benefits, it must provide meaningful benefits for that mental health condition or substance use disorder in every classification in which medical or surgical benefits are provided. Whether the benefits provided are meaningful benefits is determined in comparison to the benefits provided for medical conditions and surgical procedures in the classification and requires, at a minimum, coverage of benefits for that condition or disorder in each classification in which the health benefit plan provides benefits for one or more medical conditions or surgical procedures. A health benefit plan does not provide meaningful benefits unless it provides benefits for a core treatment for that condition or disorder in each classification in which the health benefit plan provides benefits for a core treatment for one or more medical conditions or surgical procedures. A core treatment for a condition or disorder is a standard treatment or course of treatment, therapy, service, or intervention indicated by generally accepted standards of behavioral, mental health, and substance use disorder care. If there is no core treatment for a covered mental health condition or substance use disorder with respect to a classification, the health benefit plan is not required to provide benefits for a core treatment for such condition or disorder in that classification, but must provide benefits for such condition or disorder in every classification in which medical or surgical benefits are provided.

Non-Quantitative Treatment Limitations

Appendix III. Illustrative, Non-Exhaustive List of NQTLs

(45 C.F.R. § 146.136(c)(4)(ii))

Illustrative, non-exhaustive list of nonquantitative treatment limitations.

Nonquantitative treatment limitations include—

(A) Medical management standards (such as prior authorization) limiting or excluding benefits based on medical necessity or medical appropriateness, or based on whether the treatment is experimental or investigative;

(B) Formulary design for prescription drugs;

(C) For plans with multiple network tiers (such as preferred providers and participating providers), network tier design;

(D) Standards related to network composition, including but not limited to, standards for provider and facility admission to participate in a network or for continued network participation, including methods for determining reimbursement rates, credentialing standards, and procedures for ensuring the network includes an adequate number of each category of provider and facility to provide services under the plan or coverage;

(E) Plan or issuer methods for determining out-of-network rates, such as allowed amounts; usual, customary, and reasonable charges; or application of other external benchmarks for out-of-network rates;

(F) Refusal to pay for higher-cost therapies until it can be shown that a lower-cost therapy is not effective (also known as fail-first policies or step therapy protocols);

(G) Exclusions based on failure to complete a course of treatment; and

(H) Restrictions based on geographic location, facility type, provider specialty, and other criteria that limit the scope or duration of benefits for services provided under the plan or coverage.

GOLD STANDARD: If there are other barriers to care that disproportionately burden people with mental health conditions or substance use disorders in your state, you may want to consider adding those to this list.

Appendix IV. **Prohibition on Discriminatory Factors and Evidentiary Standards (45 C.F.R. § 146.136(c)(4)(i))**

Prohibition on discriminatory factors and evidentiary standards. For purposes of determining comparability and stringency under this section, a plan (or health insurance coverage) may not rely upon discriminatory factors or evidentiary standards to design a nonquantitative treatment limitation to be imposed on mental health or substance use disorder benefits. A factor or evidentiary standard is discriminatory if the information, evidence, sources, or standards on which the factor or evidentiary standard are based are biased or not objective in a manner that discriminates against mental health or substance use disorder benefits as compared to medical/surgical benefits.

(1) Information, evidence, sources, or standards are considered to be biased or not objective in a manner that discriminates against mental health or substance use disorder benefits as compared to medical/surgical benefits if, based on all the relevant facts and circumstances, the information, evidence, sources, or standards systematically disfavor access or are specifically designed to disfavor access to mental health or substance use disorder benefits as compared to medical/surgical benefits. For purposes of this paragraph, relevant facts and circumstances may include, but are not limited to, the reliability of the source of the information, evidence, sources, or standards, including any underlying data; the independence of the information, evidence, sources, and standards relied upon; the analyses and methodologies employed to select the information and the consistency of their application; and any known safeguards deployed to prevent reliance on skewed data or metrics. Information, evidence, sources, or standards are not considered biased or not objective for this purpose if the plan or issuer has taken the steps necessary to correct, cure, or supplement any information, evidence, sources, or standards that would have been biased or not objective in the absence of such steps.

(2) For purposes of this paragraph, historical plan data or other historical information from a time when the plan or coverage was not subject to PHS Act section 2726 or was not in compliance with PHS Act section 2726 are considered to be biased or not objective in a manner that discriminates against mental health or substance use disorder benefits as compared to medical/surgical benefits, if the historical plan data or other historical information systematically disfavor access or are specifically designed to disfavor access to mental health or substance use disorder benefits as compared to medical/surgical benefits, and the plan or issuer has not taken the steps necessary to correct, cure, or supplement the data or information.

Appendix V. **Outcomes Data & Material Difference Standard**
(45 C.F.R. 146.136(c)(4)(iii))

To ensure that a nonquantitative treatment limitation applicable to mental health or substance use disorder benefits in a classification, in operation, is no more restrictive than the predominant nonquantitative treatment limitation applied to substantially all medical/surgical benefits in the classification, a plan or issuer must collect and evaluate relevant data in a manner reasonably designed to assess the impact of the nonquantitative treatment limitation on relevant outcomes related to access to mental health and substance use disorder benefits and medical/surgical benefits and carefully consider the impact as part of the plan's or issuer's evaluation. As part of its evaluation, the plan or issuer may not disregard relevant outcomes data that it knows or reasonably should know suggest that a nonquantitative treatment limitation is associated with material differences in access to mental health or substance use disorder benefits as compared to medical/surgical benefits. The [Department of Insurance] may specify in guidance the type, form, and manner of collection and evaluation for the data required under this paragraph.

GOLD STANDARD: State law can require specific data points to be collected. In addition to any data that you believe would be appropriate or helpful in your state, we recommend identifying the following data points as required by your state law, which were listed as optional in the regulations:

The number and percentage of claims denials

- In-network and out-of-network utilization rates (including data related to provider claim submissions)
- Network adequacy metrics (including time and distance data, and data on providers accepting new patients)
- Provider reimbursement rates (for comparable services and as benchmarked to a reference standard).

Appendix IV. **Comparative Analysis (45 C.F.R. § 146.137)**

(a) **In general.** *In the case of a health plan that provides both medical/surgical benefits and mental health or substance use disorder benefits and that imposes any nonquantitative treatment limitation on mental health or substance use disorder benefits, the plan or issuer must perform and document a comparative analysis of the design and application of each nonquantitative treatment limitation applicable to mental health or substance use disorder benefits. Each comparative analysis must comply with the content requirements of this section.*

(b) **Comparative analysis content requirements.** *With respect to each nonquantitative treatment limitation applicable to mental health or substance use disorder benefits under a health plan, the comparative analysis performed by the plan or issuer must include, at minimum, the elements specified in this paragraph. In addition to the comparative analysis for each nonquantitative treatment limitation, each plan or issuer must prepare and make available to the [Department of Insurance], upon request, a written list of all nonquantitative treatment limitations imposed under the plan or coverage.*

(i) **Description of the nonquantitative treatment limitation.** *The comparative analysis must include, with respect to the nonquantitative treatment limitation that is the subject of the comparative analysis:*

(i) *Identification of the nonquantitative treatment limitation, including the specific terms of the plan or coverage or other relevant terms regarding the nonquantitative treatment limitation, the policies or guidelines (internal or external) in which the nonquantitative treatment limitation appears or is described, and the applicable sections of any other relevant documents, such as provider contracts, that describe the nonquantitative treatment limitation;*

(ii) *Identification of all mental health or substance use disorder benefits and medical/surgical benefits to which the nonquantitative treatment limitation applies, including a list of which benefits are considered mental health or substance use disorder benefits and which benefits are considered medical/surgical benefits; and*

(iii) *A description of which benefits are included in each classification.*

(2) Identification and definition of the factors and evidentiary standards used to design or apply the nonquantitative treatment limitation. *The comparative analysis must include, with respect to every factor considered or relied upon to design the nonquantitative treatment limitation or apply the nonquantitative treatment limitation to mental health or substance use disorder benefits and medical/surgical benefits:*

(i) Identification of every factor considered or relied upon, as well as the evidentiary standards considered or relied upon to design or apply each factor and the sources from which each evidentiary standard was derived, in determining which mental health or substance use disorder benefits and which medical/surgical benefits are subject to the nonquantitative treatment limitation; and

(ii) A definition of each factor, including:

(A) A detailed description of the factor;

(B) A description of each evidentiary standard used to design or apply each factor (and the source of each evidentiary standard) identified under paragraph (b)(2)(i) of this section; and

(C) A description of any steps the plan or issuer has taken to correct, cure, or supplement any information, evidence, sources, or standards that would otherwise have been considered biased or not objective in the absence of such steps.

(3) Description of how factors are used in the design and application of the nonquantitative treatment limitation. *The comparative analysis must include a description of how each factor identified and defined under paragraph (b)(2) of this section is used in the design or application of the nonquantitative treatment limitation to mental health and substance use disorder benefits and medical/surgical benefits in a classification, including:*

(i) A detailed explanation of how each factor identified and defined in paragraph (b)(2) of this section is used to determine which mental health or substance use disorder benefits and which medical/surgical benefits are subject to the nonquantitative treatment limitation;

(ii) An explanation of the evidentiary standards or other information or sources (if any) considered or relied upon in designing or applying the factors or relied upon in designing and applying the nonquantitative treatment limitation, including in the determination of whether and how mental health or substance use disorder

benefits or medical/surgical benefits are subject to the nonquantitative treatment limitation;

(iii) If the application of the factor depends on specific decisions made in the administration of benefits, the nature of the decisions, the timing of the decisions, and the professional designations and qualifications of each decision maker;

(iv) If more than one factor is identified and defined in paragraph (b)(2) of this section, an explanation of:

(A) How all of the factors relate to each other;

(B) The order in which all the factors are applied, including when they are applied;

(C) Whether and how any factors are given more weight than others; and

(D) The reasons for the ordering or weighting of the factors; and

(v) Any deviations or variations from a factor, its applicability, or its definition (including the evidentiary standards used to define the factor and the information or sources from which each evidentiary standard was derived), such as how the factor is used differently to apply the nonquantitative treatment limitation to mental health or substance use disorder benefits as compared to medical/surgical benefits, and a description of how the plan or issuer establishes such deviations or variations.

(4) **Demonstration of comparability and stringency as written.** The comparative analysis must evaluate whether, in any classification, under the terms of the plan (or health insurance coverage) as written, any processes, strategies, evidentiary standards, or other factors used in designing and applying the nonquantitative treatment limitation to mental health or substance use disorder benefits are comparable to, and are applied no more stringently than, the processes, strategies, evidentiary standards, or other factors used in designing and applying the nonquantitative treatment limitation with respect to medical/surgical benefits. The comparative analysis must include, with respect to the nonquantitative treatment limitation and the factors used in designing and applying the nonquantitative treatment limitation:

(i) Documentation of each factor identified and defined in paragraph (b)(2) of this section that was applied to determine whether the nonquantitative treatment limitation applies to mental health or substance use disorder benefits and medical/surgical benefits in a classification, including, as relevant:

(A) Quantitative data, calculations, or other analyses showing whether, in each classification in which the nonquantitative treatment limitation applies, mental health or substance use disorder benefits and medical/surgical benefits met or did not meet any applicable threshold identified in the relevant evidentiary standard to determine that the nonquantitative treatment limitation would or would not apply; and

(B) Records maintained by the plan or issuer documenting the consideration and application of all factors and evidentiary standards, as well as the results of their application;

(ii) In each classification in which the nonquantitative treatment limitation applies to mental health or substance use disorder benefits, a comparison of how the nonquantitative treatment limitation, as written, is designed and applied to mental health or substance use disorder benefits and to medical/surgical benefits, including the specific provisions of any forms, checklists, procedure manuals, or other documentation used in designing and applying the nonquantitative treatment limitation or that address the application of the nonquantitative treatment limitation;

(iii) Documentation demonstrating how the factors are comparably applied, as written, to mental health or substance use disorder benefits and medical/surgical benefits in each classification, to determine which benefits are subject to the nonquantitative treatment limitation; and

(iv) An explanation of the reasons for any deviations or variations in the application of a factor used to apply the nonquantitative treatment limitation, or the application of the nonquantitative treatment limitation, to mental health or substance use disorder benefits as compared to medical/surgical benefits, and how the plan or issuer establishes such deviations or variations, including:

(A) In the definition of the factors, the evidentiary standards used to define the factors, and the sources from which the evidentiary standards were derived;

(B) In the design of the factors or evidentiary standards; or

(C) In the application or design of the nonquantitative treatment limitation.

(5) Demonstration of comparability and stringency in operation. The comparative analysis must evaluate whether, in any classification, in operation, the processes, strategies, evidentiary standards, or other factors used in designing and applying

the nonquantitative treatment limitation to mental health or substance use disorder benefits are comparable to, and are applied no more stringently than, the processes, strategies, evidentiary standards, or other factors used in designing and applying the limitation with respect to medical/surgical benefits. The comparative analysis must include, with respect to the nonquantitative treatment limitation and the factors used in designing and applying the nonquantitative treatment limitation:

(i) A comprehensive explanation of how the plan or issuer evaluates whether, in operation, the processes, strategies, evidentiary standards, or other factors used in designing and applying the nonquantitative treatment limitation to mental health or substance use disorder benefits in a classification are comparable to, and are applied no more stringently than, the processes, strategies, evidentiary standards, or other factors used in designing and applying the nonquantitative treatment limitation with respect to medical/surgical benefits, including:

(A) An explanation of any methodology and underlying data used to demonstrate the application of the nonquantitative treatment limitation, in operation;

(B) The sample period, inputs used in any calculations, definitions of terms used, and any criteria used to select the mental health or substance use disorder benefits and medical/surgical benefits to which the nonquantitative treatment limitation is applicable;

(C) With respect to a nonquantitative treatment limitation for which relevant data is temporarily unavailable, a detailed explanation of the lack of relevant data, the basis for the plan's or issuer's conclusion that there is a lack of relevant data, and when and how the data will become available and be collected and analyzed; and

(D) With respect to a nonquantitative treatment limitation for which no data exist that can reasonably assess any relevant impact of the nonquantitative treatment limitation on relevant outcomes related to access to mental health and substance use disorder benefits and medical/surgical benefits, a reasoned justification as to the basis for the conclusion that there are no data that can reasonably assess the nonquantitative treatment limitation's impact, an explanation of why the nature of the nonquantitative treatment limitation prevents the plan or issuer from reasonably measuring its impact, an explanation of what data was considered and rejected, and documentation of

any additional safeguards or protocols used to ensure that the nonquantitative treatment limitation complies with parity;

(ii) Identification of the relevant data collected and evaluated;

(iii) Documentation of the outcomes that resulted from the application of the nonquantitative treatment limitation to mental health or substance use disorder benefits and medical/surgical benefits, including:

(A) The evaluation of relevant data; and

(B) A reasoned justification and analysis that explains why the plan or issuer concluded that any differences in the relevant data do or do not suggest the nonquantitative treatment limitation contributes to material differences in access to mental health or substance use disorder benefits as compared to medical/surgical benefits;

(iv) A detailed explanation of any material differences in access demonstrated by the outcomes evaluated under paragraph (b)(5)(iii) of this section, including:

(A) A reasoned explanation of any material differences in access that are not attributable to differences in the comparability or relative stringency of the nonquantitative treatment limitation as applied to mental health or substance use disorder benefits and medical/surgical benefits (including any considerations beyond a plan's or issuer's control that contribute to the existence of material differences) and a detailed explanation of the bases for concluding that material differences are not attributable to differences in the comparability or relative stringency of the nonquantitative treatment limitation; and

(B) To the extent differences in access to mental health or substance use disorder benefits are attributable to generally recognized independent professional medical or clinical standards or carefully circumscribed measures reasonably and appropriately designed to detect or prevent and prove fraud and abuse that minimize the negative impact on access to appropriate mental health and substance use disorder benefits, and such standards or measures are used as the basis for a factor or evidentiary standard used to design or apply a nonquantitative treatment limitation, documentation explaining how any such differences are attributable to those standards or measures; and

(v) A discussion of the actions that have been or are being taken by the plan or issuer to address any material differences in access to mental health or substance use disorder benefits as compared to medical/surgical benefits, including the actions the plan or issuer has taken or is taking to address material differences to comply, in operation, with parity including, as applicable:

(A) A reasoned explanation of any material differences in access to mental health or substance use disorder benefits as compared to medical/surgical benefits that persist despite reasonable actions that have been or are being taken; and

(B) For a plan or issuer designing and applying one or more nonquantitative treatment limitations related to network composition, a discussion of the actions that have been or are being taken to address material differences in access to in-network mental health and substance use disorder benefits as compared to in-network medical/surgical benefits.

(6) Findings and conclusions. The comparative analysis must address the findings and conclusions as to the comparability of the processes, strategies, evidentiary standards, and other factors used in designing and applying the nonquantitative treatment limitation to mental health or substance use disorder benefits and medical/surgical benefits within each classification, and the relative stringency of their application, both as written and in operation, and include:

(i) Any findings or conclusions indicating that the plan or coverage is or is not (or might or might not be) in compliance with the requirements of parity, including any additional actions the plan or issuer has taken or intends to take to address any potential areas of concern or noncompliance;

(ii) A reasoned and detailed discussion of the findings and conclusions described in paragraph (b)(6)(i) of this section;

(iii) Citations to any additional specific information not otherwise included in the comparative analysis that supports the findings and conclusions described in paragraph (b)(6)(i) of this section not otherwise discussed in the comparative analysis;

(iv) The date the analysis is completed and the title and credentials of all relevant persons who participated in the performance and documentation of the comparative analysis; and

(v) If the comparative analysis relies upon an evaluation by a reviewer or consultant considered by the plan or issuer to be an expert, an assessment of each expert's qualifications and the extent to which the plan or issuer ultimately relied upon each expert's evaluation in performing and documenting the comparative analysis of the design and application of the nonquantitative treatment limitation applicable to both mental health or substance use disorder benefits and medical/surgical benefits.

Appendix VII. Consumer Access to Information (45 C.F.R. 146.137(e))

Requests for a copy of a comparative analysis.

(a) In addition to making a comparative analysis available to the Department of Insurance on an annual basis, a plan or issuer must make available a copy of the comparative analysis when requested by:

(1) Any applicable State authority; and

(2) A participant or beneficiary (including a provider or other person acting as a participant's or beneficiary's authorized representative).

(b) A plan or issuer must provide the requested comparative analysis no later than 30 calendar days after receiving a request under paragraph (a)(2)

(c) A plan or issuer may not withhold any information contained in the comparative analysis, including any information from or developed by third parties.

Enforcement

Appendix VIII. Enforcement (45 C.F.R. §§ 146.136(c)(4)(v)(A), 146.137(d))

(a) **Requirements related to submission of comparative analyses to the [Department of Insurance]**—

(1) **Initial submission for comparative analysis.** A health plan must submit the comparative analysis to the [Department of Insurance] on [date], and annually thereafter, in the manner required by this section.

(2) **Requirement to notify participants and beneficiaries of final determination of noncompliance** —

(i) **In general.** If the [Department of Insurance] makes a final determination of noncompliance, the plan or issuer must notify all participants and beneficiaries enrolled in the plan or coverage that the plan or issuer has been determined to not be in compliance with the requirements of parity or this section with respect to such plan or coverage. Such notice must be provided within 7 business days of receipt of the final determination of noncompliance, and the plan or issuer must provide a copy of the notice to the [Department of Insurance], any service provider involved in the claims process, and any fiduciary responsible for deciding benefit claims within the same timeframe.

(ii) **Content of notice.** The notice to participants and beneficiaries shall be written in a manner calculated to be understood by the average plan participant and must include, in plain language, the following information in a standalone notice:

(A) The following statement prominently displayed on the first page, in no less than 14-point font: “Attention! The [Department of Insurance] has determined that [insert the name of group health plan or health insurance issuer] is not in compliance with the Mental Health Parity and Addiction Equity Act.”;

(B) A summary of changes the plan or issuer has made as part of its corrective action plan specified to the Secretary following the initial determination of noncompliance, including an explanation of any opportunity for a participant or beneficiary to have a claim for benefits submitted or reprocessed;

(C) A summary of the [Department of Insurance’s] final determination that the plan or issuer is not in compliance with parity or this section, including any provisions or practices identified as being in violation, additional corrective actions identified by the [Department of Insurance] in the final determination notice, and information on how participants and beneficiaries can obtain from the plan or issuer a copy of the final determination of noncompliance;

(D) Any additional actions the plan or issuer is taking to come into compliance with parity or this section, when the plan or issuer will take such actions, and a clear and accurate statement explaining whether the Secretary has concurred with those actions; and

(E) Contact information for questions and complaints, and a statement explaining how participants and beneficiaries can obtain more information about the notice, including:

(1) The plan's or issuer's phone number and an email or web portal address;
and

(2) The [Department of Insurance's] phone number and email or web portal address.

(iii) **Manner of notice.** The plan or issuer must make the notice available in paper form, or electronically (such as by email or an internet posting) if:

(A) The format is readily accessible;

(B) The notice is provided in paper form free of charge upon request; and

(C) In a case in which the electronic form is an internet posting, the plan or issuer timely notifies the participant or beneficiary in paper form (such as a postcard) or email, that the documents are available on the internet, provides the internet address, includes the statement required in this section, and notifies the participant or beneficiary that the documents are available in paper form upon request.

(b) **Effect of final determination of noncompliance.** If a health plan receives a final determination from the [Department of Insurance] or applicable State authority that the plan or issuer is not in compliance with the comparative analysis requirements with respect to a nonquantitative treatment limitation, the nonquantitative treatment limitation violates parity and the [Department of Insurance] or applicable State authority may direct the plan or issuer not to impose the nonquantitative treatment limitation with respect to mental health or substance use disorder benefits in the relevant classification, unless and until the plan or issuer demonstrates to the [Department of Insurance] or applicable State authority compliance with the requirements of this section or takes appropriate action to remedy the violation.

GOLD STANDARD: Add financial penalties to the section on the effects of a final determination of compliance, consistent with your state's laws. Your state may already have direct authority to impose penalties for violations of parity, though you could also tie them to unfair and deceptive trade practices, acts of discrimination, or failure to submit timely or sufficient form filings.

Penalties

Below are two existing state examples, from Georgia and Massachusetts.

Georgia has financial penalties in statute, though regulators may wish to consider monetary penalties large enough to act as a deterrent rather than the cost of doing business.

Georgia Code 33-1-27(i) ²⁵

(1) If the Commissioner determines that a health insurer failed to submit a timely or sufficient report required under paragraph (4) of subsection (b) of this Code section or failed to submit timely and sufficient data pursuant to a data call conducted pursuant to paragraph (1) of subsection (c) of this Code section, the Commissioner may impose a monetary penalty of up to \$2,000.00 for each and every act in violation, unless the insurer knew or reasonably should have known that he or she was in violation, in which case the monetary penalty may be increased to an amount of up to \$5,000.00 for each and every act in violation.

(2) If the Commissioner determines that an insurer failed to comply with any provision of this Code section, the Commissioner may take any action authorized, including, but not limited to, issuing an administrative order imposing monetary penalties, imposing a compliance plan, ordering the insurer to develop a compliance plan, or ordering the insurer to reprocess claims.

Massachusetts has penalties determined per person affected:

Massachusetts Gen. Law Ch. 26 Sec. 8k(b) ²⁶

(b) The commissioner may impose a penalty against a carrier that provides mental health or substance use disorder benefits, directly or through a behavioral health manager as defined in section 1 of chapter 176O or any other entity that manages or administers such benefits for the carrier, for any violation by the carrier or the entity that manages or administers mental health and substance use disorder benefits for the carrier of state laws related to mental health and substance use disorder parity or the mental health parity provisions of the federal Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008, 42 U.S.C. 300gg-26, as amended, and federal guidance or regulations issued under the act.

The amount of any penalty imposed shall be \$100 for each day in the noncompliance period per product line with respect to each participant or beneficiary to whom such violation relates; provided, however, that the maximum annual penalty under this subsection shall be \$1,000,000; provided further, that for purposes of this subsection, the term “noncompliance period” shall mean the period beginning on the date a violation first occurs and ending on the date the violation is corrected.

A penalty shall not be imposed for a violation if the commissioner determines that the violation was due to reasonable cause and not to willful neglect or if the violation is corrected not more than 30 days after the start of the noncompliance period.

References

- ¹ Department of the Treasury, Department of Labor, & Department of Health & Human Services, “Requirements Related to the Mental Health Parity and Addiction Equity Act,” 89 Fed. Reg. 77586, 77702 (September 23, 2024)
- ² Note: The Parity Act also applies to Medicaid managed care plans, the Medicaid expansion population (alternative benefit plans), and the Children’s Health Insurance Program (CHIP). However, these final rules only apply to private insurance plans. However, states should consider applying these standards to Medicaid as well. Please see our issue brief on Medicaid Gold Standards [link when available] for more information on how to mirror these requirements for Medicaid.
- ³ See Appendix I for model language
- ⁴ See 45 C.F.R. 146.136(a)(2)
- ⁵ See Appendix II for model language
- ⁶ See § 146.136(c)(2)(ii)(A)
- ⁷ For more information on how states can implement generally recognized independent standards of current medical practice in fidelity to the federal law, see our issue brief [link when available]
- ⁸ See Appendix III for model language
- ⁹ See § 146.136(c)(4)(ii)
- ¹⁰ See Appendix IV for model language
- ¹¹ See § 146.136(c)(4)(i)
- ¹² See Appendix V for model language
- ¹³ See § 146.136(c)(4)(iii)

- 14** See § 146.136(c)(4)(iii)(A)(1)
- 15** See Appendix VI for model language
- 16** See § 146.137
- 17** See Appendix VII for model language
- 18** See § 146.136(d)(3); § 146.137(e)(2)
- 19** See 29 CFR § 2590.712(d)(3)
- 20** See Appendix VIII for model language
- 21** See § 146.137(e)(1)
- 22** See § 146.137(d)
- 23** See § 146.136(c)(4)(v)(A)
- 24** This authority gives state regulators greater leverage to compel health plans to take parity reporting and remediation of noncompliance findings seriously, particularly during market conduct exams. For example, a state regulator can send the request to the issuer for a comparative analysis on an NQTL, indicating that an insufficient comparative analysis can be deemed out of compliance with 42 U.S.C. 300gg-26(a)(8)(A) and 45 CFR 146.137(c).
- 25** <https://codes.findlaw.com/ga/title-33-insurance/ga-code-sect-33-1-27/>
- 26** <https://malegislature.gov/Laws/GeneralLaws/PartI/TitleII/Chapter26/Section8K>
- 27** For more detail, see The Kennedy Forum’s Analysis of the Mental Health Parity Final Rule from September 10, 2024 <https://www.thekennedyforum.org/blog/analysis-of-the-mental-health-parity-final-rule/> and the Legal Action Center’s summary <https://www.lac.org/assets/files/LAC-fact-sheet-2024-Parity-Regulations-final.pdf>
- 28** See § 146.136(c)(4)(iii)(A)(2)